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Abstract 
 
  Mutation of tumor suppressor Adenomatous Polyposis Coli (APC) is an early, if 
not the first step in the majority of colorectal cancers. As a multi-functional protein, APC 
has been implicated in regulating cell cycle and cytoskeletal integrity. To further 
understand APC function in cell cycle regulation, I immunoprecipitated APC and 
identified novel associated proteins. I identified topoisomerase IIα (topo IIα), a critical 
regulator of the G2 decatenation checkpoint, as a potential binding partner of APC. The 
interaction of endogenous APC and topo IIα  was verified by co-immunoprecipitation, 
co-localization, and Förster resonance energy transfer (FRET). Both the fifteen (M2-APC) 
and twenty (M3-APC) amino acid repeat regions of APC interacted with topo IIα when 
expressed in cultured cells. Cells expressing M2- or M3-APC arrested in G2, but only if 
the cells contain normal levels of topo IIα. This G2 cell cycle arrest likely resulted from 
reduction of endogenous topo IIα activity, consistent with the established model whereby 
inhibition of topo IIα activates the G2 decatenation checkpoint.   
APC has been shown to interact with microtubules and the actin cytoskeleton, 
inplicating APC in cell polarity and migration. Using a novel APC antibody raised 
against M2-APC, I co-immunoprecipitated potential APC binding proteins from 
HCT116βw cells. I identified 42 proteins in complex with APC by Liquid 
Chromatography Tandem Mass Spectrometry (LC-MS/MS). Among these were 
intermediate filament (IF) proteins lamin B1 and keratin 81. Lamin B1 interacts with 
APC in both cultured cells and human colonic tissue. APC also associated with IF 
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proteins throughout a sequential extraction procedure, which removed actin 
microfilaments and microtubules.  
Based on evidence described in this dissertation, I hypothesize that two central 
APC domains interact with topo IIα to regulate the G2 decatenation checkpoint. In 
addition, I also provide evidence supporting a role for APC in the regulation of 
cytoskeletal integrity. 
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CHAPTER 1 
INTRODUCTION: COLORECTAL CANCER, 
 ADENOMATOUS POLYPOSIS COLI & CELL CYCLE REGULATION   
Part I. Pathogenesis of Colorectal Cancer 
Colorectal cancer (CRC) is the third most common type of cancer and the second 
leading cause of cancer-related deaths in the United States. It is estimated that in 2008 
there were 108,070 CRCs diagnosed and 49,960 deaths (1). CRC develops slowly in the 
terminal six to seven feet of the digestive tract, called the large intestine, which includes 
colon and rectum. The large intestine is responsible for absorption of water and mineral 
nutrients (1). The colon can be divided into two sections: the proximal colon, which 
connects to the small intestine; and the distal colon, which joins with the rectum. Benign 
lesions called adenomatous polyps can form from the intestinal epithelium. A small 
percentage of a these polyps eventually become cancers, called adenocarcinoma. Over 
95% of all CRCs are thought to arise from adenomatous polyps (1).  
The colonic epithelium 
The intestinal lining contains three tissue layers: the innervated smooth muscle that 
executes peristalsis; the submucosa that contains connective tissue and mesenchyme; and 
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the mucosa, which is a sheet of epithelial cells (Figure 1.1). The epithelial layer is 
composed of three major cell types: absorptive enterocytes; enteroendocrine cells that 
secrete hormones; and goblet cells that secrete a protective mucus barrier. The epithelial 
layer invaginates into the submucosa, forming crypts. It is estimated that 4-6 stem cells 
reside at the bottom of each crypt (2, 3). Although the stem cells are predominantly 
quiescent, occasionally they divide and give rise to progenitor transient amplifying (TA) 
cells (Figure 1.1). These progenitor cells undergo continuous divisions. Each progeny 
from these progenitor cells is committed to a specific cell lineage. As progeny cells 
differentiate, they migrate toward the luminal surface of the gut. Whether these terminal 
differentiated enterocytes undergo apoptosis before they shed into the lumen is still 
controversial, although apoptotic cells have been found in the colonic crypts (4). 
The intestinal epithelium continuously proliferates. The entire colonic crypt can 
repopulate in about 5 days (5). Therefore, a tightly regulated program that balances cell 
proliferation, differentiation, and cell death is required to ensure the integrity of the 
intestinal epithelium. Changes that cause imbalances in the system can contribute to 
tumor initiation. This exquisite control is not only programmed into the epithelium, but 
also in the adjacent mesenchyme, which send signals to epithelial cells that control 
proliferation, cell fate choices, terminally differentiation, and death (6, 7). 
Differentiated cells
Transient 
amplifying cells
Figure 1.1
Structure of the colonic epithelia. Normal colon epithelia invaginates to form “crypt”
structures. Each crypt comprises stem cells and transient amplifying (TA) cells in the 
progenitor compartment. As TA cells migrate up, they cease proliferation and begin to 
differentiate. Once TA cells reach the luminal surface, they are sloughed off into the 
lumen. (Adapted from Sancho and Clevers, 2004)
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Molecular Pathogenesis of CRC  
Although CRC was first described in the 18th century, the associated genetic defects 
were not revealed until the early 1990s (8). Inherited syndromes associated with CRC 
include Familial Adenomatous Polyposis (FAP), Hereditary Nonpolyposis Colorectal 
Cancer (HNPCC) and Hamartomatous Polyposis syndromes (9). FAP patients develop 
numerous adenomatous polyps and carry germline mutations in the Adenomatous 
Polyposis Coli (APC) gene (10-12). HNPCC patients develop fewer polyps and carry 
germline mutations in genes of the DNA mismatch repair (MMR) pathway (13, 14). 
Hamartomatous Polyposis syndrome is characterized by lesions involving mesenchymal 
tissues. One such syndrome, Juvenile Polyposis Syndrome (JPS), is associated with 
mutations in SMAD-4 and BMPR1A genes (15).  
Half of the western population will develop at least one adenomatous polyp by the 
age of 70 (16). Mutation in APC is considered the first step in polyp formation and APC 
mutations are found in nearly 85% of all CRCs examined (17). CRCs with mutant APC 
are aneuploid and display chromosomal instability (CIN). In contrast, CRCs initiated by 
mutations in any of the five human MMR genes, hMSH2, hMLH1, hMSH6, hPMS1 and 
hPMS2 (13, 18-20) display microsatellite instability (MIN) (21). Microsatellites are 
tandem repeats of DNA sequences that are variable in length and found throughout the 
genome. In cells with mutations in DNA repair genes, microsatellites are abnormally 
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longer or shorter, referred to as microsatellite instability. HNPCC accounts for less than 
2-4% of all CRCs (22). There are other CRCs associated with MIN. Some cancers with 
MIN posses mutations in other genes related to DNA repair such as GTBP, MSH3 or 
polymerase δ (23-25). In addition to the CRCs with CIN and MIN, another ~5% of 
sporadic CRCs are thought to originate from sessile serrated adenomas with active 
mutation of the BRAF gene (26, 27). 
Knudson established a “two-hit” hypothesis of tumor suppressor inactivation based 
on his statistical analysis of a type of childhood tumor that occurs in the retina, called 
retinoblastoma. Children with hereditary retinoblastoma inherit one mutant allele of the 
Retinoblastoma (Rb) gene (28). Mutation of the second Rb gene rapidly leads to cancer. 
Therefore, children with sporadic retinoblastoma develop cancer at an older age, because 
it takes longer to acquire mutations in both Rb genes than it does to develop a mutation in 
only the second Rb allele as required in the hereditary form. According to this “two-hit” 
tumor suppressor hypothesis, after the first APC gene is inactivated either in germline or 
in somatic cells, the second wild-type APC allele must also gain somatic mutation for 
APC to completely lose its function as a tumor suppressor (29, 30). Complete inactivation 
of APC has been observed in the majority of early human neoplastic lesions (30, 31). In 
mice with germline Apc mutations similar to those found in FAP patients, the wild-type 
Apc allele is always inactivated or lost in polyps (30). Whereas APC mutations are 
thought to initiate polyp formation; and mutations in genes other than APC are required 
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for tumorigenesis. It is believed that at least seven genetic mutations are required for 
tumorigenesis in human (32). Colorectal tumor starts from lesions called aberrant crypt 
foci (ACF), which are precursors of adenomatous polyps (32). Only a subset of ACF 
bearing APC and K-RAS mutations gives rise to adenomatous polyps that eventually 
progress to malignancy (33). In recent years, a “multiple hit hypothesis” has been 
proposed which suggests that multiple genetic mutations are required after an initial 
selective advantage to acquire malignant transformation. 
Vogelstein proposed a classical model for colorectal tumorigenesis, in which at least 
three steps are required: initiation, promotion and progression (8). CRC results from 
inactivation of tumor suppressors in combination with activation of oncogenes (8). In 
FAP patients, germline mutations in APC are thought to be responsible for 
hyperproliferation, which allows additional mutations to accumulate (Figure 1.2A). 
Activating mutation of oncogene K-RAS in a preexisting adenoma can lead to a larger and 
more dysplastic tumor. Inactivating mutations in tumor suppressor SMAD-4 and 
Transforming Growth Factor Receptor II (TGFβRII) may occur in some cells and thus 
provide a selective growth advantage to those cells. Loss of tumor suppressor gene P53 
often happens during the progression from adenoma to cancer. Although almost 85% of 
all CRCs are thought to initiate with mutations in APC, they do not necessarily share the 
classical order of these genetic events (mutations in APC, then KRAS, then p53) described 
in the “Vogelgram” (Figure 1.2A). It is thought that the accumulation of mutations in 
Figure 1.2
Sequential genetic changes in the pathogenesis of CRC. (A)  Vogelgram of model for 
most FAP and some sporadic CRCs initiated from APC mutations (Adapted from 
Kinzler KW and Vogelstein B, 1996). A tumor evolves through a series of mutations of 
oncogenes and tumor suppressor genes. Only cells acquiring these mutations progress 
toward advanced lesions. (B)  Events happening in HNPCC and many of the remaining 
sporadic CRCs. (Adapted from Voutsadakis, 2007) Epigenetic events such as CpG
islands methylation happen in both models but are more frequent in (B).
APC
β-catenin
K-Ras
B-Raf
Smad4
TGFβ RII
P53
Other mutations
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Epithelium
Dysplastic
ACF
Early
Adenoma
Late
Adenoma Cancer
Metastatic
Cancer
Hypomethylation
Nuclear β-catenin levels & chromosome instability
A.  Chromosome Instability 
B.  Microsatellite Instability 
Epigenetic
Events
MSH2
MLH1  Mutations
PMS2
Microsatellite 
Instability
Frequent Mutations 
throughout Genome Cancer
 8
key regulatory genes is more important for tumorigenesis than the exact order of these 
genetic events (8).  
In another pathway that leads to HNPCC, mutations in DNA mismatch repair genes 
result in microsatellite instability (Figure 1.2B) (34). Defects in DNA repair cause 
alterations in the microsatellite DNA repeats resulting in variable repeat lengths, and 
frequently in codon frame shifts (35, 36). In addition, epigenetic changes, such as 
aberrant DNA methylation, can occur in early stages of CRC (37). Specific genes such as 
hMLH1 and BRAF are often found to be inactivated by hypermethylation [reviewed in 
(38)]. These epigenetic events destabilize chromosomes and thus, potentially promote 
additional mutations.  
Part II. Adenomatous Polyposis Coli 
APC gene and protein 
The human APC gene is located on chromosome 5q21-q22 and consists of 15 exons 
(10, 11). APC encodes a protein of 2843 amino acids (~312kDa) with multiple domains 
to which numerous proteins bind (Figure 1.3) (10, 11, 17). APC contains an 
oligomerization domain, an armadillo repeat-domain, a number of 15- or 20- amino acid 
(aa) repeats, a basic domain, and binding sites for end-binding protein 1 (EB1) and discs 
large (DLG). Most mutations of APC occur in a region called the mutation cluster region 
Figure 1.3
Structure of human APC protein. Multiple domains of APC are indicated in colors. 
Binding sites for APC-interacting proteins are indicated as well.  N-terminal coil-coiled 
domain is responsible for APC oligomerization. Armadillo repeats mediate the 
interaction with IQGAP and ASEF. The 15-aa and 20-aa repeats are involved in β-
catenin binding and down-regulation. SAMP repeats bind Axin. The basic domain binds 
to microtubules. The C-terminal domain binds to EB1 and DLG. (Modified from Aoki 
and Taketo 2007.)
PDZ 
binding 
domain
Oligomerization 
domain
β-catenin binding 
& down-regulation
MCR
IQGAP, ASEF & 
KAP3 binding
Microtubule  
binding
EB1 
binding 
domain
Basic 
domainArmadillo repeats
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(MCR) (39, 40). These mutations typically result in a premature translational stop 
between codons 1250 and 1450 and expression of just the N-terminal portion of the APC 
protein. The N-terminal coiled-coil domain of APC enables APC to form dimers (41). 
Both wild-type and truncated mutant APC are thought to form homo- or hetero-dimers 
(41, 42). The armadillo repeats of APC are nearly identical to regions of armadillo 
protein, the Drosophila homologue of mammalian β-catenin (11). There are three 15-aa 
repeats and seven 20-aa repeats in APC, which provide docking sites for β-catenin (43, 
44). Although the 15-aa repeats are sufficient for β-catenin binding (43), the 20-aa 
repeats are required for β-catenin down-regulation (45). Contained within the 20-aa 
repeats are three SAMP repeat sequences, which mediate Axin-binding (46).  
Within the C-terminus of APC there is a region comprising of predominantly basic 
amino acids (aa 2200-2400) (10). This basic domain and EB1 binding domain both bind 
to microtubules and can simulate tubulin polymerization in vitro (47, 48). The extreme 
C-terminal portion of APC contains a Post Synaptic Density Discs Large Zonula 
Occludens (PDZ) binding domain, including the STXV amino acid sequence. PDZ 
proteins DLG (49), protein tyrosine phosphatase–BL (PTP-BL) (50) and hScrib (51) have 
been reported to bind to the PDZ-binding domain of APC.  
APC mRNA is highly expressed during embryogenesis (52). In adult animals, it is 
expressed in all tissues (53), with its highest expression in brain and colon (52). In normal 
human colonic tissue, APC protein predominantly localizes to the basolateral membrane 
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and cytoplasm of enterocytes, with some nuclear localization as well (17, 54, 55). 
Interestingly, the basolateral staining in colonic epithelial cells is increasingly 
pronounced as cells migrate from the bottom of the crypt toward the luminal surface (17, 
53, 54, 56). Although some studies have reported apical plasma membrane localization of 
APC in mouse colonic enterocytes (57), it is now generally accepted that this staining 
represents protein(s) other than APC that are recognized by some commercial APC 
antibodies (58-60). In cultured colonic cells, APC has been detected in the cytoplasm and 
nucleus, at the plasma membrane, and at the tips of microtubules (61-64). This complex 
subcellular localization pattern of APC suggests that different pools of APC protein are 
involved in different cellular functions, such as cell adhesion and microtubule 
stabilization. Given the multiple functional domains of APC, its numerous binding 
partners, and the biological consequence of APC inactivation, it is likely that APC 
functions to integrate different signaling pathways to maintain cellular homeostasis.  
APC in Wnt signaling 
A major advance in our understanding of the role of APC in suppression of CRC 
came from the discovery of an association between APC and β-catenin (43, 44). APC 
forms a complex in combination with Axin and Glycogen synthase kinase 3β (GSK3β) to 
inhibit β-catenin activity to suppress the canonical Wnt signaling pathway (46). 
Canonical Wnt signaling plays vital roles throughout development (65). The central 
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component of Wnt signaling is β-catenin (gene name CTNNB1). In the presence of a 
soluble Wnt ligand, Wnt receptor Frizzled, together with co-receptor LRP5/6, blocks the 
binding and phosphorylation of β-catenin by the APC complex, leading to accumulation 
of β-catenin in the cytoplasm [reviewed in (65)] (Figure 1.4). Cytoplasmic β-catenin 
translocates into the nucleus, complexes with members of the T-cell factor/lymphoid 
enhancing factor (TCF/LEF) family of transcription factors to initiate transcriptions of 
Wnt target genes (66, 67), such as Cyclin D1 and MYC (68). To suppress Wnt signaling, 
APC complex interacts with β-catenin (69, 70), phosphorylates β-catenin by GSK3β and 
Casein Kinase I (CKI) at the N-terminal Ser/Thr sites to promote its ubiquitination by E3 
ubiquitin ligase β-transducing repeat-containing protein (β-TrCP) that targets it for 
proteosomal degradation (71). Wnt ligand also activates non-canonical Wnt signaling 
pathways, such as the planar cell polarity (PCP) pathway and a pathway involving Ca2+ 
signaling, for which we have limited mechanistic and functional information (72).  
Although most truncated forms of APC retain part of the β-catenin binding domain, 
they lose regions critical for β-catenin destruction.  As a result, human adenomas with 
APC mutations often display increased levels of nuclear β-catenin (73, 74). Analysis of 
several mouse models has confirmed that mutation of Apc leads to intestinal 
tumorigenesis (75-78). APCMin (Multiple intestinal neoplasia) mice possess a wild-type 
and a mutant Apc allele, the later encoding a nonsense mutation at codon 850 (77, 78). 
APCΔ716 mice produce a truncated APC protein containing the first 716 amino acids (75). 
Figure 1.4
Model of APC regulation of β-catenin-mediated Wnt singling. Wnt ligands bind to 
frizzled receptor to activate disheveled, which inhibits phosphorylation of β-catenin and 
prevents its proteosomal degradation. Accumulated β-catenin translocates into the  
nucleus to activate downstream target genes. APC acts as a scaffold together with Axin 
and GSK3β to recruit β-catenin, and, target it for ubiquitination by β-TrCP and 
proteosomal degradation. In the nucleus, APC also inhibits β-catenin by sequestering it 
or by direct interacting with a repressor complex containing β-TrCP.
β-TrCP
Axin
APC   
Wnt
Disheveled
GSK3β
GSK3β
β-catenin
Proteasome
β-catenin
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Mice from both models develop numerous polyps in their small intestines and display 
nuclear β-catenin as an indication of active Wnt signaling (76, 78). APC1638 mice, which 
express a less truncated APC protein, develop fewer tumors in the small intestine, thus 
are widely used for long term study of tumor progression (79). A more recently generated 
transgenic mouse model expressing a dominant stable β-catenin also develops small 
intestinal tumors, thus providing direct evidence that Wnt signaling is involved in 
intestinal tumorigenesis (80). Although less frequent than adenomas with mutant APC, 
human adenomas with mutant stabilized β-catenin but wild-type APC also exist (81). 
Nevertheless, tumors in mouse models with loss of APC function are found in multiple 
tissues, beyond those found in mice with activated β-catenin (80, 82). Although evidence 
provided from analysis of human adenoma and mouse models suggests the importance of 
Wnt signaling in colorectal tumorigenesis, APC appears to have functions beyond Wnt 
signaling. 
Nuclear APC 
APC has been observed to localize to the nuclei of both cultured cells (83) and 
mouse and human intestinal tissues (56, 84). In addition, both endogenous and 
epitope-tagged APC have been observed to localize to the nucleoli, although the APC 
function at this location is unclear (55, 83). Two nuclear localization signals (NLSs) have 
been identified in APC at aa 1767-1772 and aa 2048-2053 (85) (Table 1.1). APC also 
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possess five nuclear export signals (NESs) (Table 1.1) (55, 86, 87). These NESs and 
NLSs enable APC to shuttle between the nucleus and cytoplasm.  
The nucleo-cytoplasmic shuttling of APC appears to facilitate APC inhibition of 
nuclear β-catenin activity by promoting its nuclear export (87-89) (Figure 1.4B). APC 
with mutated NESs is not able to efficiently target β-catenin for destruction, implicating 
APC in the nuclear export of β-catenin (87). However, both full-length APC and a central 
fragment of APC (aa 1379-2080) each with mutated NESs was able to down-regulate 
nuclear β-catenin activity, implicating nuclear APC in the sequestration of nuclear 
β-catenin (87, 88). A more recent study using chromatin immunoprecipitation (CHIP) 
demonstrated that APC binds to the MYC enhancer region in a repressor complex 
containing β-TrCP, C-terminal binding protein (CtBP) and histone deacetylase 1 
(HDAC1) (90, 91). These studies provide evidence that APC inhibits Wnt signaling in 
ways other than by forming a cytoplasmic β-catenin destruction complex.  
APC may directly bind to A/T-rich regions of DNA through clusters of S/TPXX 
located in the basic domain (92). In addition, APC also interacts with nuclear proteins 
involved in DNA repair. APC has been proposed to participate in long patch base 
excision repair (LP-BER) through interaction with DNA polymerase β and its cofactor 
proliferating cell nuclear antigen (PCNA) (93). APC blocks LP-BER by interacting with 
flap endonuclease 1 (Fen-1).  Thus, APC is implicated in DNA damage-induced 
carcinogenesis (94). 
Table 1.1 NLSs and NESs amino acid (aa) sequence and position information
LSSLSI2027-2032NES-R6
LSALSL1506-1511NES-R3
LLERLKELNL68-76NES1
GKKKKP1767-1772NLS1
LSDLTI1657-1662NES-R4
LTKRIDSLPL165-173NES2
PKKKKP2048-2053NLS2
aa sequenceaa positionNLS/NES
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APC and cytoskeletal integrity 
Cell proliferation, differentiation and migration synergize to maintain intestinal 
epithelial integrity [reviewed in section I]. The observation that APC can interact with the 
cytoskeleton suggests a role for APC in colonic cell architecture (95-97). APC has been 
reported to interact with microtubules and stabilize them by inhibiting depolymerization 
(47, 48, 98). APC has also been found to associate with EB1 at the basal cortex of 
polarized epithelial cells (99). Interaction of APC with actin filaments was inhibited by 
introducing purified recombinant EB1 in vitro (100). Disruption of the APC/EB1 
interaction restored APC localization to actin (100). Colocalization of APC with EB1 on 
centrosomes also indicates a potential role for APC in the dynamics of microtubules and 
mitotic spindles (101, 102). In migrating cells, APC binds to EB1 at the microtubule plus 
end and thus potentially regulates microtubule integrity (97). APC lacking the 
EB1-binding domain binds microtubules throughout their length with no preference for 
microtubule plus end binding, suggesting the interaction of EB1 with APC is important 
for targeting APC to microtubule plus ends (103). 
APC participates in the actin network by interacting with IQGAP, an activator for 
cell division cycle 42 (Cdc42) at the leading edge of migrating cells (95, 104). Depletion 
of either APC or IQGAP disrupts actin filament formation and polarized cell migration 
(95). APC also binds to a Rac specific GEF, APC-stimulated guanine nucleotide 
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exchange factor (ASEF), to stimulate actin polymerization (96). Interaction of APC with 
ASEF results in activation of Cdc42, thus suppressing anchorage-independent growth 
(105). Therefore, APC appears to stimulate cell polarization and suppress tumor 
formation through binding to IQGAP and ASEF and ultimately stimulating Cdc42.  
APC is a junctional protein, colocalizing with β-catenin at cell adhesions (44). 
However, β-catenin, an adherense junction protein that interacts with E-cadherin, does 
not appear able to bind to both APC and E-cadherin at the same time (106). This 
exclusive binding suggests that the junctional APC/β-catenin interaction also participates 
in the suppression of tumorigenesis. Furthermore, forced expression of APC in a mouse 
model results in defects in cell migration, indicating the APC-β-catenin and 
E-cadherin-β-catenin complexes have opposing roles in epithelial movement (56). 
Besides β-catenin, APC was also reported to interact with DLG, a scaffolding protein 
associated with cell junctions (49). DLG contains three PDZ domains, which APC binds. 
APC/DLG interaction at the leading edge of epithelial cells is required for microtubule 
and basal membrane association (107).  
Most mutations in APC result in expression of a truncated protein. This truncated 
APC loses direct binding sites for many protein partners such as EB1. Deletion of the 
PDZ-binding domain of APC abolishes APC plasma membrane localization and cell 
substrate attachment, therefore disturbing cell spreading and migration (108). In contrast, 
restoring full-length APC to colon cancer cells enhances cell adhesion (109). Truncated 
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APC lacks the PDZ binding domain, which provides a link to the actin cytoskeleton 
through DLG and other PDZ domain-containing proteins. Therefore, it has been 
hypothesized that APC mutations affect the cytoskeleton and thus, contribute to tumor 
initiation or progression.  
So far, APC has been found to directly associate with two of the three major 
components of the cytoskeleton: actin filaments and microtubules. It will be of interest to 
study if APC also associates with the third component: intermediate filaments. My 
finding of APC interaction with IF proteins Lamin B1 and Keratin 81 linked APC to all 
three components of the cytoskeleton [see Chapter 4 for detail]. This study further 
supports functions of APC in regulating the cytoskeleton integrity thus preventing 
tumorigenesis.  
APC and cell cycle regulation 
 Various studies support a role for APC in cell cycle regulation, especially in mitosis. 
In mitotic cells, APC localizes to the kinetochore, mitotic spindle and centrosomes (101, 
110-112). However, it is still debated whether APC is required in the processes of spindle 
formation and chromosome segregation. Using Xenopus extracts, APC was shown to be 
required for spindle formation (110). Loss of APC resulted in kinetochore dysfunction 
and inhibition of apoptosis, leading to aneuploidy (113). Truncated APC fragments were 
shown to have dominant-negative effects on spindle formation, compromising 
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kinetochore-microtubule interactions and thus inducing CIN (114, 115). The observation 
that mutations in APC induce CIN supports the idea that APC functions in chromosome 
segregation (112, 115-117). On the other hand, others have reported that reduction of 
APC did not interfere with the spindle checkpoint or the stability of the 
kinetochore-microtubule interaction. However, APC reduction did cause chromosome 
mis-segregation (118). These differences may stem from distinctions between full-length 
APC and overexpressed truncated APC protein. It is also possible that APC functions in 
different pools. Only a small portion of full-length APC is required to maintain its 
function at kinetochore-microtubules. In contrast, ectopic expression of truncated APC 
protein might exhibit a dominant-negative effect. Nevertheless, germline Apc mutations 
in mice result in CIN, as evidenced by aneuploidy and chromosomal defects in 
embryonic stem (ES) cells and cells of polyps (112, 113, 117, 119). However, human 
adenoma studies failed to provide definitive evidence supporting the link between loss of 
APC and CIN (120). In addition, localization of APC at the midbody during cytokenesis 
has also been reported, although the APC function at this location is unclear (121).  
 Evidence suggests that APC functions throughout the cell cycle. Expression of APC 
in NIH3T3 fibroblast cells blocked the cell cycle in G1, by inhibiting transcription of 
Cyclin D1 through the Wnt signaling pathway (122). Expression of full-length APC in a 
colon cancer cell line with only endogenous truncated APC also resulted in G1 arrest 
(123). The APC-DLG complex has been implicated in this G1-S cell cycle arrest (124). 
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Mutant APC lacking the DLG binding site failed to block cell cycle in G1; however, the 
mechanism is unknown. A recent study showed that full-length APC negatively regulated 
cell cycle progression into or through S phase by inhibiting DNA replication (125). On 
the other hand, reduced expression of APC mRNA has been reported in cells undergoing 
G1 arrest induced by DNA-damaging agent MNNG (126). Zinc-induced stabilization of 
APC induces G2 cell cycle arrest in HCT116 cells that express full-length APC (127).  
β-catenin stabilization can also lead to G2/M cell cycle arrest (111). However, this arrest 
potentially reflects β-catenin’s ability to sequester endogenous APC (128). Together, 
these studies suggest that APC participates in cell cycle regulation in a variety of cell 
types. The mechanism by which APC regulates G1/S cell cycle progression is 
presumably through suppressing Cyclin D1 in Wnt signaling. However, how does APC 
regulate G2/M cell cycle progression is less understood. Therefore, I focus on studying 
potential pathways through which APC controls G2-M cell cycle transition [see detail in 
Chapter 2&3]. 
Part III. Topoisomerase IIα 
 In an attempt to clarify the role of APC in cell cycle control, we identified a novel 
interaction between APC and topoisomerase IIα (topo IIα), a key regulator of the G2 
decatenation checkpoint. Thus, I now introduce the basic biology of topo IIα protein. 
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Topo II enzyme and DNA topology 
 The intertwining feature of the DNA double helix (129) suggests that many 
biological process, such as DNA replication, are highly dependent on DNA topology 
(130). DNA is commonly under-wound or over-wound, making it difficult to separate the 
double helix to initiate replication, transcription, or other processes (131). In addition, 
knots and tangles accumulate during DNA recombination and replication. If not properly 
untangled during cell division, these knots will lead to cell death (132). Topoisomerases 
are enzymes that modulate DNA topology changes by creating transient breaks at 
phosphodiester bonds in the backbone of DNA double helices (133, 134). In eukaryotes, 
there are two types of topoisomerases with distinct catalytic mechanisms. Topoisomerase 
I (topo I) induces single-strand nicks in the double helix followed by single strand DNA 
passage to alleviate super-helical twists (135-137). Topo I is thus involved in most DNA 
processes to maintain genomic integrity (138). Topoisomerase II (topo II) generates 
double-strand breaks followed by a second double-strand DNA passage. Topo II is 
thought to be involved in more cellular activities than topo I (138-140).  
Two human topo II genes have been identified: TOP2α, mapped to chromosome 
17q21-22 (141); and TOP2β, mapped to chromosome 3q24 (142). The 170kDa topo IIα  
and the 180kDa topo IIβ  are ~70% identical in amino acid sequence (143) and have 
similar primary structures. There are three major domains in topo II based on their 
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homology to bacterial and yeast topo II and proteolytic sites (Figure 1.5A) (136, 144, 
145). The N-terminal domain (aa 1-~454) contains the ATP binding site (146). The 
central domain (aa ~454-~1263) contains the active tyrosine site that is required for DNA 
cleavage and re-ligation (138, 147). The C-terminal domain (aa ~1263-1521) is highly 
variable between two isoforms, thus may be responsible for the differences in the 
biological functions between topo IIα and β. This domain, although not required for topo 
II catalytic activity in vitro, contains the NLSs (148-150) and phosphorylation sites 
(151-153). The crystal structure of the catalytic domains in yeast topo II has been solved 
(Figure 1.5B) (144). The central domain of human topo IIα is homologous to the 
B-subunit and A-subunit of yeast topo II.   
Topo IIα and topo IIβ function as homodimers to catalyze double-stranded DNA 
passage and facilitate changes in DNA topology (144, 154). A topo II dimer binds to two 
segments of DNA ---- the gated DNA helix and the transported DNA helix (Figure 1.6) 
(138-140, 144, 155). Upon ATP binding, the topo II dimer generates a double-strand 
break in the gated DNA helix, undergoes conformational change to form a closure that 
traps both segments in the central hole. This enzyme-cleaved DNA complex is called 
“cleavage complex”. The nick in the gated DNA helix produces a “gate” to allow a 
second transported DNA helix to pass. Topo II then re-joins the DNA ends in the gated 
DNA helix and releases both DNA helixes by opening the dimer formed by B-subunits 
and C-terminal domains. 
ATPase Variable
N-terminal 
domain
Central domain C-terminal 
domain
Y805702 1263
NH2 COOH
Figure 1.5
Structure of eukaryotic topo II protein. (A) The three domains of human topo IIα:  N-
terminal domain (yellow), Central domain (red and blue), and C-terminal domain (light 
blue), which is highly variable. Proteolytic cleavage sites are indicated at aa-454, aa-702 
and aa-1263. The active site tyrosine residue Y805 is shown in pink. (B) Crystal 
structure of the catalytic active domain of yeast topo II (amino acid 401-1202). (Berger 
and Wang, 1996) 
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Figure 1.6
A molecular model of topo II catalytic action. DNA topo II is composed of three 
domains: ATPase domain (yellow), B’ domain (red), and A’ domain (blue). (A) The 
topo II dimer binds to the gated DNA helix (light blue). (B) The transported DNA helix 
(green) enters the complex between the ATPase domains. Meanwhile, ATP (stars) binds 
the complex to induce cleavage in the gated DNA helix and conformation change in the 
topo II dimer. (C) The transported DNA helix thus passes through the break in the gated 
DNA helix. (D) The intermediate “cleavage complex” is transient. rejoins the breaks in 
the gated DNA helix, and opens the closure to release the transported DNA helix. ATP 
is then hydrolyzed to prepare the enzyme for the next round of catalytic reaction. 
(Modified from Berger and Wang, 1996) 
A
B
C
D
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Topo IIα and the G2 decatenation checkpoint 
Topo IIα and topo IIβ display similar enzymatic features, however, exhibit distinct 
expression patterns and physiological functions. Topo IIα expression fluctuates during 
cell cycle due to changes in mRNA stability (156, 157). Generally, topo IIα protein 
increases during cell proliferation, and progressively decreases when cells differentiate 
(143, 156). During cell cycle, topo IIα mRNA increases when cells progress from G0/G1 
phase to S phase, reaching its maximum in G2 (158, 159). Topo IIα expression gradually 
declines toward the end of mitosis. In contrast, topo IIβ protein level and activity remain 
steady throughout the cell cycle (143, 156). Topo IIα accumulates at mitotic centromeres 
and during prophase of meiosis [reviewed in (145)]. The cell cycle-dependent expression 
pattern suggests a potential role for topo IIα in cell cycle control. The increasing level of 
topo IIα phosphorylation in G2/M of the cell cycle (158-160) also indicates a role for 
topo IIα in cell cycle regulation. 
Mammalian cell lines lacking topo IIβ are viable in culture, suggesting that topo IIβ 
is dispensable for cell cycle progression, and topo IIα is sufficient for mitosis (161-163). 
Topo IIα has been shown to involve in chromosome condensation and segregation, 
although its precise role remains unclear. When treated with topo II poisons or inhibitors, 
cultured mammalian cell lines exhibit G2 arrest right before entering M phase (164-166). 
In most cases, topo II poisons trap DNA within the “cleavage-complex”. Therefore, the 
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cell cycle arrest observed resembles activation of the G2 checkpoint in response to DNA 
damage. However, in cases where topo II inhibitors, such as ICRF-193, do not induce 
formation of the stable “cleavage-complex”, G2 cell cycle arrest still occurs (167-169). 
These results indicate that accumulation of incomplete decatenation of interlinked DNA 
due to topo II inhibitors or poisons halts cells at the G2 phase of the cell cycles thus 
activating the decatenation checkpoint. This G2 decatenation checkpoint delays mitotic 
entry until chromosomes are properly decatenated (168).  
At present, our understanding of the G2 decatenation checkpoint is still limited. Until 
recently, only topo IIα was known to directly control the G2 decatenation checkpoint 
(170). The most popular current model, although lacking direct supporting evidence, is 
described in Figure 1.7 (171). The decatenation checkpoint is dependent on ATM- and 
Rad3-related kinase (ATR), which mediates the delay by inhibiting Polo-like kinase 1 
(Plk1) (172). In normal cell cycle progression, Plk1 phosphorylates cyclin B1 to promote 
nuclear import of the cyclin B1/Cdk1 complex and thus execute cell cycle progression 
into mitosis (173). Treatment with topo II inhibitor ICRF-193 reduces Plk1 activity, thus 
inhibiting the G2-M transition by activating the decatenation checkpoint (173). Breast 
cancer 1 (BRCA1) and Werner helicase (WRN) are also required for the G2 decatenation 
checkpoint (172, 174). Mutation of either BRCA1 or WRN results in defects in the 
decatenation checkpoint. Restoration of a wild type BRCA1 or WRN reverses these 
defects.  
Topo IIα
ATR
Plk1
Cyclin B1
WRN BRCA1
Figure 1.7
A molecular model of G2 decatenation checkpoint. Topo IIα is required to detangle 
chromosomes in G2 before entering M. If chromosome is not properly decatenated, 
ATR kinase can be activated in the presence of WRN and BRCA1. ATR kinase in turn 
inhibits Plk1, which is required for cyclin B1 phosphorylation and cyclin B1/Cdk1 
nuclear localization. As a result, the decatenation checkpoint is activated and G2-M 
transition is delayed.  (Modified from Damelin and Bestor, 2007) 
G2 M
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Topo IIα also acts as a scaffold for p53 and Cdc2 (175). Cdc2 kinase association 
with chromatin is dependent on interaction with topo IIα. Inactivation of Cdc2 kinase is 
believed to induce G2 arrest (176). Therefore, inhibition of topo IIα activity may also 
perturb the G2-M transition through compromising Cdc2 activation. However, whether 
topo IIα is required for chromosome condensation is still controversial. One study 
reported that association between Cdc2 and topo IIα was required for chromatin 
condensation at the onset of mitosis using nuclear extract from chicken embryos (177). 
While others showed that in Hela cells with topo IIα efficiently knocked down using 
siRNA, chromosomes were properly condensed and mitotic spindles were assembled 
(178). These cells did not display any defects in G2-M transition either. These seemingly 
contradictory results, however, were obtained from two completely different systems.  
On the one hand, the in vitro chicken embryo nuclear extract may not function properly 
like a chicken embryo under normal physiological conditions. On the other hand, as 
transformed cancer cells, Hela cells may have escaped some important growth 
restrictions and thus might not have normal biological responses upon depletion of topo 
IIα protein. Further in vivo studies are required to reveal definitive biological functions of 
topo IIα in the G2-M transition and the mitotic regulation.  
To better understand how topo IIα regulates cell cycle, identification of novel topo 
IIα binding partners that is involved in decatenation checkpoint is a practical approach. 
Such studies should be encouraged to explore the biological relevance of topo IIα 
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binding proteins. Thus, in Chapter 2&3, I introduced the finding of interaction between 
topo IIα and APC, the latter of which is also involved in G2/M cell cycle progression. 
Studying the functional interaction between these two proteins helps obtain mechanistic 
information of the topo IIα-dependent G2 decatenation checkpoint. 
Topo IIα and CRC 
Topo IIα expression is restricted to tissues containing many cycling cells, such as 
thymus, spleen, bone marrow, intestine and testis (179-181). In contrast, topo IIβ is 
detectable in a wider rage of tissues, but at a lower level than topo IIα, if both are present 
(180). In the normal colon, topo IIα expression is limited to the proliferative zone. 
However, topo IIα is up-regulated in many colon cancer tissues (182). At primary 
locations of recurrent malignant colon tumors following chemotherapy, the number of 
topo IIα-positive cells greatly increased compared to at primary sites with no recurrence 
(183). A recent study looking for biomarkers of CRC found TOP2α mRNA up-regulated 
four-fold in cancer compared to normal tissue (184).  
Topoisomerases participate in almost all cellular functions involving DNA. 
Therefore, studies of topoisomerases have spanned both pharmacology and clinical 
medicine: from identification of antibiotics to target DNA gyrase in bacteria (185-187) to 
anticancer agents that target human topo I and II (188-191). Drugs targeting topo II have 
focused on topo IIα, because drug-resistant cell lines with eliminated topo IIβ have been 
 31
generated, suggesting cells lacking topo IIβ are viable (192). Most drugs are topo II 
poisons, targeting topo II by stabilizing the cleavage complex (193, 194). The resulting 
accumulation of double-stranded DNA breaks is toxic to cells. Other drugs inhibit topo II 
activity but do not stabilize the cleavage complex and some can prevent the transported 
DNA helix from passing through (195). The exact mechanisms of inhibition by these 
drugs that target topo II requires further investigation.  
Although topo II poisons have been widely used as chemotherapeutic agents, cellular 
drug-resistance is a problem. Defects in the decatenation checkpoint have been observed 
in cultured normal stem cells, resulting in an increasing potential for genomic instability 
(196). Therefore, it has been proposed that cancer stem cells have similar defects, thus 
leading to tumor growth and progression by rapid generation of addition mutations (171). 
Further studies on cancer cell lines and tissues will add to our understanding of the 
importance of the decatenation checkpoint in tumorigenesis and tumor progression.  
Part IV. Summary 
The homeostasis of the intestinal epithelium is tightly controlled by complex 
synergism between multiple regulatory pathways. As discussed, no two CRCs are exactly 
alike and thus, their genesis can not be explained by a single oncogenic mechanism. 
Rather, CRCs result from the interplay of distinct mutations acting under different 
physiological conditions. Mutation of APC is clearly a key factor for colorectal 
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tumorigenesis. Loss of functional APC may affect intestinal epithelial homeostasis by 
altering a single pathway, such as Wnt signaling. However, extensive cross-talk between 
multiple functions of APC adds complexity to understanding the contribution of each 
APC activity. The combination of various effects makes APC a powerful tumor 
suppressor protein. Further study of some of the less understood APC functions, such as 
cell cycle regulation and cytoskeletal organization, will help elucidate how multiple 
pathways cooperate to prevent carcinogenesis. In the following chapters, we present 
evidence for a role of APC in the topo IIα-dependent G2-M transition and in intermediate 
filament regulation. 
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CHAPTER 2  
INTERACTION BETWEEN TUMOR SUPPRESSOR APC & TOPOISOMERASE IIα:  
IMPLICATION FOR THE G2/M TRANSITION 
Abstract 
 The tumor suppressor APC is implicated in regulating multiple stages of the cell 
cycle. APC participation in G1/S is attributed to its recognized role in Wnt signaling.  
APC function in the G2/M transition is less well established. To identify novel protein 
partners of APC that regulate the G2/M transition, APC was immunoprecipitated from 
colon cell lysates and associated proteins were analyzed by MALDI-TOF.  
Topoisomerase IIα (topo IIα) was identified as a potential binding partner of APC. Topo 
IIα is a critical regulator of G2/M transition. Evidence supporting an interaction between 
endogenous APC and topo IIα was obtained by co-immunoprecipitation, colocalization, 
and FRET. The 15 amino acid repeat region of APC (M2-APC) interacted with topo IIα 
when expressed as a GFP-fusion protein in vivo. Although lacking defined nuclear 
localization sequences, M2-APC predominantly localized to the nucleus. Furthermore, 
cells expressing M2-APC displayed condensed or fragmented nuclei and were arrested in 
the G2 phase of the cell cycle. Although M2-APC contains a β-catenin binding domain, 
biochemical studies failed to implicate β-catenin in the observed phenotype. Finally, 
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purified recombinant M2-APC enhanced topo IIα activity in vitro. Together, these data 
support a novel role for APC in the G2/M transition, potentially through association with 
topo IIα.  
Introduction 
The tumor suppressor protein adenomatous polyposis coli (APC) is inactivated in 
over 80% of all colorectal cancers (1). The detection of mutant APC in the earliest stages 
of polyp development supports the idea that mutation of APC is an initiating event in 
colon carcinogenesis. The most common form of APC mutation results in elimination of 
the carboxy-terminal half of the APC protein. Because APC is a large, multi-domain 
protein, APC truncation is predicted to impact a number of cellular mechanisms, the 
extent of which we are only beginning to understand.  
There is accumulating evidence supporting a role for APC in the regulation of the 
cell cycle. Over-expression of APC in NIH3T3 fibroblasts and colon cancer cell lines 
leads to G1 cell cycle arrest (2, 3), presumably by repressing transcription of Wnt targets 
such as cyclin D1. APC may also participate directly in mitosis as it is transiently 
hyperphosphorylated in the M phase of the cell cycle (4), accumulates at the microtubule 
organizing center (5) and associates with the kinetochore in dividing cells (6, 7).  A role 
for APC in mitosis might be critical for regulation of genomic stability and proper 
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chromosome segregation. APC stabilized by zinc treatment induces G2/M cell cycle 
arrest in colon cancer cells (8). However, to date, little is known about the underlying 
mechanism by which APC participates in the G2/M cell cycle transition. 
Here we report identification of topoisomerase IIα (topo IIα) as a potential APC 
binding protein. Topo IIα enzyme catalyzes DNA topology changes by introducing 
double strand DNA breaks that facilitate DNA strand passage and subsequent DNA 
re-ligation (9-12). Topo IIα has been implicated in a number of cellular functions such as 
DNA replication and chromosome condensation (9, 11-15), and appears essential in the 
control of the G2/M decatenation checkpoint during cell division (16). Topo IIα was also 
found to be deregulated in colon cancers with its expression limited to the proliferative 
zone in the normal colon, but up-regulated and widespread in colon cancer tissue (17). At 
primary locations of recurrent malignant colon tumors following chemotherapy, the 
number of topo IIα-positive cells is greatly increased compared to primary sites with no 
recurrence (18), suggesting that changes in topo IIα expression occur subsequent to APC 
mutation. Together, these observations make topo IIα an attractive candidate for 
mediating the G2/M cell cycle transition. 
Over-expression of an APC fragment that interacts with topo IIα in various colon 
cancer cells lines led to abnormal nuclear morphology and cell cycle inhibition in G2.  
 52
Our data suggest a novel role for nuclear APC in the regulation of cell cycle progression, 
potentially through an interaction with topo IIα.  
Materials and Methods 
Cell culture and DNA constructs 
 HCT116βw cells (a generous gift from Dr. Bert Vogelstein) were grown in McCoy’s 
5A medium (Gibco) supplemented with 10% FBS (Hyclone). Expression constructs for 
APC fragments fused to GFP were kindly provided by Dr. Naoki Watanabe and have 
been described previously (19).  
Antibodies and immunofluorescence microscopy  
Immunostaining was performed as described (20) and the following antibodies were 
used: anti-APC (ab-7, 1:50, Calbiochem), anti-APC (ab-4, 1:2000, Calbiochem), 
anti-APC (ab-1, 1:100, Calbiochem), anti-topo IIα ( 1:100, Research Diagnostics, Inc.), 
anti-phospho-histone H3 (1:500, Upstate), anti-β-catenin (1:200, Transduction Lab) and 
anti-PCNA (1:1000, Transduction Lab); goat anti-mouse IgG Alexa 488 (1:1000, 
Molecular Probes), goat anti-rabbit IgG Alexa 568 (1:1000, Molecular Probes), and goat 
anti-mouse IgG Alexa 610-R-phycoerythrin (1:500, Molecular Probes). DNA was labeled 
with Topro-3 (1:500, Molecular Probes) or DAPI (1:5000, Invitrogen). 2-D and 3-D 
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distributions of immunofluorescent signals were examined using a Yokugawa-type 
spinning disk confocal microscope equipped with an Olympus 150X objective with a 
N.A. of 1.45 and 1KX1K EMCCD (Olympus and Intelligent Imaging Innovations, 
Denver, Co.). From over 200 cells that viewed, 50 cells were randomly chosen to be 
imaged. No less than 24 image frames were collected at z-intervals of 100 nm for image 
sets where 3-D co-localization was examined. No deconvolution was performed. All raw 
confocal image series were analyzed by ImageJ program and the JACoP plugin without 
further processing. Mitotic indices were determined by counting DAPI-stained mitotic 
cells in a field of 100 cells for each repetition.   
Protein co-localization analysis 
Colocalization coefficients were calculated using ImageJ and the JACoP plugin (21). 
Using Costes’ method of automatic thresholding, a Pearson’s coefficient was calculated 
for pixels within all of the calculated regions of interest in an image where Alexa 488 and 
Alexa 568 fluorescence were each detected at levels significantly above background. 
Mander’s coefficients were also calculated in order to determine the degree of overlap 
between the corresponding regions of detected signals. 
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FRET analysis  
Evidence of Förster resonance energy transfer (FRET) between secondary 
fluorophores was detected using a Zeiss 510 Meta spectral imaging upright laser scanning 
confocal microscope. Donor fluorescence, alternatively from Alexa 488 or Alexa 610-R- 
phycoerythrin was photo-bleached by passing the beam of the 543 nm laser (at 100% 
output) over defined regions of interest (ROI) for 75 iterations or using 200 passes of the 
633 nm laser (also 100% output). Close proximity of the two proteins was determined by 
calculating the mean FRET efficiency between donor and acceptor according to the 
method of Kenworthy and Edidin (22) where E=100(Alexa 488post-Alexa 
488pre)/Alexa488post or E=100(Alexa 610-R-PEpost-Alexa 610-R-PE pre)/Alexa 610-R-PE 
post. All pixels within the photo-bleached regions were used for these calculations. Error 
bars indicate the Standard Error of the Mean (SEM). Three dimensional reconstructions 
and projections were also performed with Image J. 
Immunoprecipitation and western immuno blots 
 Immunoprecipitation (IP) and western immuno blots (IB) were performed using 
modified standard protocols. Cells at 90% confluency were lysed in lysis buffer [50 mM 
Tris pH7.5, 0.1% NP40, 100 mM NaCl, 1 mM MgCl2, 5 mM EDTA, protease inhibitor 
cocktail (Sigma), and Halt phosphatase inhibitor cocktail (PIERCE)] on ice for 30 
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minutes. Cell lysates were sonicated for 10 pulses, level 1 with 10% output, 3 times. 
Specific antibodies were pre-incubated with Protein A dynabeads (Invitrogen) for 2 hours 
at room temperature. Dynabeads saturated with antibodies were added to 1mg of soluble 
lysate and incubated overnight at 4°C. IP pellets were subject to two washes of 15 
minutes using lysis buffer and one wash using PBS-T at 4°C. The following antibodies 
were used for IP: anti-topo IIα sera (a generous gift from Dr. Joe Holden), affinity 
purified anti-APC-M2 rabbit polyclonal antibody made against amino acid 1000-1326, 
and polyclonal anti-GFP (Invitrogen). Immunoblots were probed with the following 
antibodies: anti-APC (ab-1, 1:100, Calbiochem), anti-APC-M2 polyclonal (1:4000), 
anti-β-catenin (1:2000, Sigma), anti-topo IIα (1:1000, Research Diagnostics, Inc.), 
anti-topo IIβ (1:1000, Santa Cruz) and anti-α-tubulin (1:2000, Oncogene).    
Transfection and reporter gene assay 
HCT116βw, SW480 and HCA7 cells were transfected using Lipofectamine2000 
reagent according to the manufacturer's protocol (Invitrogen). For luciferase assays, 
HCT116βw cells grown in 24-well plate were cotransfected with 2 μg of the 
GFP-M2-APC or GFP expression construct, 100 ng of the TCF-reporter construct 
SuperTOP-flash or FOPflash (Upstate Biotechnology, Lake Placid, NY), and 50 ng of the 
pRL-TK Renilla luciferase construct (Promega, WI) as a control to normalize the 
transfection efficiency. After 24 hrs, cells were harvested and luciferase activities were 
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determined using Dual-Luciferase® assay system (Promega) and a Turner Designs 
TD-20/20 luminometer. SuperTOP-flash and FOPflash luciferase activities were first 
normalized by pRL-TK Renilla luciferase, and then the normalized SuperTOP-flash 
luciferase activity was divided by normalized FOPflash luciferase activity to calculate 
relative β-catenin activity.   
FACScan analysis 
 Propidium iodide staining of GFP expressing cells in suspension was performed 
using a standard protocol as described (23). HCT116βw cells at 35% confluency were 
transfected using Lipofectamine 2000 (Invitrogen). 30 hours post transfection, cells were 
fixed with 2% paraformaldehyde (Electron Microscopy Science) on ice for 1 hour, 
followed by overnight permeabilization using 70% ethanol in PBS. Rehydrated cells were 
then stained with 40 μg/ml propidium iodide (Sigma) in PBS for 30 minutes at 37°C. 
FACS analysis was performed using a Beckton Dickinson FACScan. 
Topo II α assays and recombinant proteins 
To generate recombinant S tag fused M2-APC, the corresponding cDNA for APC 
(amino acid 1000-1326) was subcloned into a pET-30a(+) vector. Both tags (S and His) 
were fused to the amino terminus of the protein. The expression and purification of 
S-M2-APC fusion protein was performed as described (24). Recombinant human topo 
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IIα was made as described (25, 26). In vitro topo IIα relaxation and decatenation assays 
were performed as described (10). 
Results 
Endogenous full-length APC associates with topo IIα 
To identify novel APC binding proteins that could potentially function to regulate 
cell cycle progression, we immunoprecipitated APC from HCT116 cell lysates, resolved 
precipitated proteins by SDS-PAGE, and visualized these proteins using coomassie blue. 
One protein in a 170 kDa band unique to APC precipitation was identified by 
MALDI-TOF analysis as topoisomerase IIα (topo IIα) [Neufeld & White, unpublished]. 
We verified the APC / topo IIα interaction in both HCT116 cells and cells derived 
from this cell line.  Although HCT116 cells were initially cultured from human colon 
cancer tissue, they express full length APC and maintain a stable karyotype.  The 
original HCT116 cell line possesses one wild-type and one mutant β-catenin allele. The 
mutant allele encodes a stabilized version of β-catenin which is not down-regulated by 
APC. The HCT116βw line we use for most experiments was engineered to eliminate the 
mutant β-catenin allele and thus, expresses only wild-type β−catenin protein (27).  
Full-length endogenous APC co-immunoprecipitated with topo IIα from HCT116 cell 
lysates (Figure 2.1A). No full-length APC was precipitated with control rabbit IgG. In 
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reciprocal experiments, topo IIα  co-precipitated with full-length APC using an affinity 
purified APC antibody, but not with preimmune sera (Figure 2.1B, left panel). We 
consistently detected nearly 2% of the total topo IIα co-precipitated with APC (Figure 
2.1B, right panel). In contrast, although topoisomerase IIβ is 75% identical to topo IIα, 
topo IIβ did not co-precipitate with APC (Figure 2.1B, left panel).  This apparent 
binding preference for topo IIα over topo IIβ increases the likelihood that the APC topo 
IIα interaction is specific. 
The subcellular distribution of endogenous APC and topo IIα further implicated topo 
IIα as a binding partner of APC. Endogenous APC was found to colocalize with topo IIα 
within single confocal slices taken through the nucleus where both appear as overlapping 
puncta (Figure 2.1C, a). When the entire cell thickness was visualized by a series of 
confocal images captured in the z-plane, areas of overlap were apparent throughout the 
nuclei (Figure 2.1C, b). To show the areas of overlap from an entire cell thickness as a 
single image, overlapping signals in the 3-D data sets were projected onto a 2-D surface 
and are displayed in yellow (Figure 2.1C, c). The degree of overlap between the 
corresponding regions was calculated for each 2-D confocal section and is displayed as 
the average for the entire imaged volume. On average, 1.9% of the topo IIα signal 
coincided with APC, and 10% of the APC signal coincided with topo IIα (Figure 2.1C,d).  
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To further examine the association between APC and topo IIα, we analyzed Förster 
resonance energy transfer (FRET) between the two immuno-labeled proteins in fixed, 
permeabilized HCT116βw cells (Figure 2.1D). Given the nature of FRET, it is estimated 
that energy transfer would be detected only if two antibody-labeled proteins are less than 
30 nm apart. Detection of an average energy transfer efficiency (E) of 20.8% between 
immunolabeled Alexa 488-APC and Alexa 568-topo IIα within photobleached regions of 
interest indicates that endogenous APC and topo IIα are in close proximity and is 
consistent with a direct interaction in colon epithelial cells. This value is significantly 
more positive than measurements performed on cells in which photobleaching was 
omitted (E=-0.9%).  Likewise, cells transiently expressing GFP showed no energy 
transfer between endogenous topo IIα and exogenous GFP (E=-5.7%), even though GFP 
was abundant in the nucleus (see e.g. Figure 2.5A). 
The 15-amino acid repeat region of APC colocalizes with topo IIα, alters nuclear 
morphology, and causes cell cycle arrest in G2 
APC is a 310 kDa protein with several distinct protein-binding domains (Figure 
2.2A). To identify potential topo IIα-binding domains in APC, we expressed five 
GFP-fused APC fragments (Figure 2.2A) in HCT116βw cells and compared their 
localizations to that of endogenous topo IIα (Figure 2.2B). As expected, GFP fused with 
either NT-APC, M1-APC or CT-APC predominantly localized to the cytoplasm (Figure 

 61
 
 
 
 
Figure 2.l 
Endogenous topo IIα associates with endogenous full-length APC. (A) Endogenous full-length 
APC co-immunoprecipitated with topo IIα using anti-topo IIα rabbit sera, but not using rabbit 
IgG. P, precipitated proteins; S, nonprecipitated supernatant proteins. Representative blot from 
eight independent experiments. (B) Full length APC immunoprecipitated with affinity purified 
polyclonal anti-APC sera (left, middle panel). Endogenous topo IIα (upper panel) 
co-immunoprecipitated with the endogenous full-length APC while topo IIβ did not (lower panel). 
Quantification of the band intensity from 3 independent experiments revealed 1.8% of the total 
topo IIα co-precipitated with full-length APC (right panel). Representative blots from seven 
independent experiments. (C) Colocalization of endogenous APC and topo IIα in HCT 116βw 
cells using APC antibody (ab-7), polyclonal topo IIα antibody and confocal microscopy. (a) 
Confocal image shows APC (green) and topo IIα (red) colocalized in the nucleus (yellow in 
Merge). Bar, 5 μm. (b) Confocal images through the entire cell thickness were collected for APC 
(green) and topo IIα (red) and are shown as a projection of the 3D Z-series images. (c) 
Overlapping pixels for the Z-series images in b are projected and shown in yellow. (d) Graph 
shows the average number of overlapping pixels calculated from six individual Z-series images.  
1.9% of the topo IIα  pixels overlap with APC, while 10% of the APC pixels overlap with topo 
IIα. (D) Measurements of Förster resonance energy transfer (FRET) between APC-Alexa 488 and 
topo IIα–Alexa 568 were performed using the method of donor fluorescence sensitization 
following acceptor photo-bleaching in fixed samples of immunofluorescently labeled HCT116βw 
cells. Endogenous APC was labeled using either anti-APC ab-1 or anti-APC ab-7 followed by 
goat anti-mouse Alexa 488 secondary antibody. Endogenous topo IIα was labeled using anti-topo 
IIα antibody followed by goat anti-rabbit Alexa 568 secondary antibody. Energy Transfer 
Efficiencies (E) between immunolabeled Alexa 488-APC and Alexa 568-topo IIα were ~20.8% 
(grey bar, left, n=10) within photobleached regions. This value is significantly positive (* p = 
0.00021) compared to E measured without photobleaching (E=-0.9%, n=10, white bar) or to 
energy transfer (E=-5.7%, n=3, grey bar, right) between photobleached GFP which is abundantly 
expressed in the nucleus and immunolabeled Alexa 488-APC (** p=0.0000000056). 
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2.2B). M3-APC (amino acids 1211-2075) contains all 20-amino acid repeats and two 
nuclear localization signals (NLS) (28) and appeared in the nucleus when fused to GFP. 
GFP fused with M2-APC (amino acids 959-1338) showed the most prominent overlap 
with topo IIα in the nucleus. This region of APC contains all four 15 amino acid 
β-catenin binding repeats and one 20 amino acid repeat but no defined NLS.  
Not only was GFP-M2-APC predominantly localized to the nucleus, but HCT116βw 
cells expressing this APC fragment displayed abnormal DNA morphology, with nuclei 
appearing condensed or fragmented (Figure 2.3A). To quantify this phenotype, 
GFP-positive cells were scored at 24, 48 and 72 hours post transfection (Figure 2.3B and 
Table 2.1). GFP-M2-APC expression resulted in a dramatic alteration in the DNA 
morphology, with 82% of the cells displaying abnormal nuclei by 48 hours post 
transfection. In contrast, expression of GFP-M3-APC or GFP alone had little effect on 
DNA morphology. Because the abnormal nuclear morphology was not prevalent in 
M3-APC- or GFP-expressing cells, but rather was limited to cells expressing M2-APC, 
this phenotype is not merely the cellular response to over-expression of a nuclear protein.  
Moreover, abnormal nuclei were also observed in SW480, HCA7 (Figure 2.3C, Table 2.2) 
and parental HCT116 cells (data not shown) expressing GFP-M2-APC. Therefore, the 
abnormal nuclear morphology is not restricted to the HCT116βw cell line and is not 
dependent on full length endogenous APC. The abnormal nuclear morphology resulting 
Figure 2.2
The 15-amino acid and 20-amino acid repeat regions of APC each colocalize with topo 
IIa and localize to the nucleus. (A) Schematic diagram of APC with domains impli-
cated in nuclear function marked. Two NLSs are designated by thin pink lines in both 
full-length APC and M3-APC.  Five APC fragments expressed as GFP fusions are 
shown. (B) Colocalization of the GFP-fused APC fragments with endogenous topo IIa 
in HCT116bw cells. Of the five APC fragments, both M2 and M3 displayed significant 
nuclear localization and partial colocalization with topo IIa. Bar, 5 mm.
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Figure 2.3 
The 15-amino acid repeat region of APC protein alters nuclear morphology. (A) Confocal 
immunofluorescence microscopy revealed abnormal nuclei (condensed or fragmented) in 
M2-APC expressing HCT116bw cells. Bar, 5 mm. (B) Nuclear phenotype of HCT116bw 
cells expressing GFP-M2-APC (light bar), GFP-M3-APC (dark bar), or GFP (white bar) 
at 24 and 48 hours post transfection. Over 80% of the M2-APC expressing cells displayed 
abnormal nuclear morphology by 48 hours. (C) Nuclear phenotype of SW480 cells and 
HCA7 cells expressing GFP-M2-APC (light bar) or GFP (white bar) at 48 hours post 
transfection. (B, C) Graphs represent analysis of 100 cells for each transfection in three 
independent experiments with error bars indicating standard deviation.
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Table 2.1 Nuclear phenotypes of HCT116βw cells expressing GFP, GFP-M2-APC or 
GFP-M3-APC 
 
  Normal DNA Abnormal DNA 
GFP 89 +/- 4 11 +/- 2 
M2-GFP 31 +/-13 69 +/-13 24 hrs 
M3-GFP 87 +/- 4 13 +/- 4 
GFP 84 +/- 6 16 +/- 6 
M2-GFP 17 +/- 11 82 +/- 12 48 hrs 
M3-GFP 85 +/- 9 15 +/- 9 
GFP 89 +/- 7 11 +/- 7 
M2-GFP 7 +/- 3 93 +/- 3 72 hrs 
M3-GFP 65 +/- 27 35 +/- 27 
For each transfection, 100 cells were chosen randomly and were scored in 3 independent 
experiments at three time points. 
 
 
Table 2.2 Nuclear phenotypes of SW480 and HCA7 cells expressing GFP, or GFP-M2-APC 
 
  SW480 HCA7 
  Normal. DNA Abnormal. DNA Normal DNA Abnormal DNA
GFP 75 +/- 5 25 +/- 5 82 +/- 5 19 +/- 5 
24 hrs 
M2-GFP 18 +/-3 82 +/-3 41 +/-6 59 +/-6 
GFP 81 +/- 5 19 +/- 5 92 +/- 4 8 +/- 4 
48 hrs 
M2-GFP 20 +/-3 80 +/-3 29 +/-13 71 +/-13 
GFP 79 +/- 7 21 +/- 7 82 +/- 14 17 +/- 16 
72 hrs 
M2-GFP 17 +/-4 83 +/-4 45 +/-7 55 +/-7 
For each transfection, 100 cells were chosen randomly and were scored in 3 independent 
experiments at three time points. 
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from M2-APC expression resembled that seen in apoptotic cells.  To determine if 
over-expression of M2-APC triggered apoptosis, we examined cells for various apoptotic 
markers such as activated caspase-3 and annexin V, but found no evidence of apoptosis 
(data not shown).  Furthermore, when the cell cycle distribution of propidium 
iodide-stained cells was analyzed using FACScan, the GFP-M2-APC expressing cells 
had no detectable sub-G0 cell population indicative of apoptotic cells (Figure 2.4A).  
Overall, the cell cycle distribution of non-transfected cells was only slightly different 
from that of GFP-expressing cells.  In contrast, the GFP-M2-APC-expressing cells 
showed a reproducible 2.5-fold increase in the G2/M phase and an accompanying 
reduction in the S phase compared to control cells (Figure 2.4B).   
To determine whether this expanded G2/M population reflected an arrest in the G2 or 
M phase of the cell cycle, mitotic indices and phospho-histone H3 expression were both 
evaluated at 24, 48 and 72 hrs post transfection (Figure 2.4, C and D). None of the 
M2-APC-expressing cells were mitotic at any time point, whereas control cells or cells 
expressing GFP alone showed typical mitotic indices at all time points examined. These 
data suggest that the expression of M2-APC results in G2 cell cycle arrest.  
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The abnormal nuclear morphology following expression of the 15-amino acid repeat of 
APC is not due to altered β-catenin  
M2-APC comprises all four of the 15 amino acid β-catenin binding repeats and one 
of the 20 amino acid repeats involved in β-catenin down-regulation (Figure 2.2A). 
Activated Wnt signaling resulting from stabilized β-catenin was recently reported to 
contribute to chromosome instability (29) and lead to G2 arrest (5). Thus, we predicted 
that the abnormal nuclear morphology seen in cells expressing M2-APC was dependent 
on M2-APC association with and stabilization of nuclear β-catenin. We found β-catenin 
expression and localization identical in HCT116βw cells expressing M2-APC, GFP, or 
non-transfected (Figure 2.5A).  Furthermore, immunoblots from total lysates 
demonstrated comparable levels of β-catenin in M2-APC- and GFP-expressing cells 
(Figure 2.5D). Moreover, less than 1% of the total β-catenin co-precipitated with 
GFP-M2-APC (Figure 2.5B). In contrast, more than 10% of the total β-catenin was 
precipitated along with endogenous full-length APC in parallel experiments under the 
same experimental conditions (Figure 2.5C). Finally, β-catenin activity measured in 
M2-APC-expressing cells was comparable to that in GFP-expressing cells (Figure 2.5E). 
Thus, it appears unlikely that the abnormal nuclear morphology and the G2 cell cycle 
arrest observed in M2-APC-expressing cells result from β-catenin sequestration by 
M2-APC.  
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Figure 2.4 
Expression of the 15-amino acid repeat region of APC results in G2 accumulation. (A) 
Histograms showing representative FACScan displays of cell cycle distribution assessed by 
propidium iodide staining. UN, untransfected cells. For both GFP and GFP-M2-APC expressing 
cells, only GFP positive cells are displayed. (B) FACScan data from three independent 
experiments. The fraction of cells in G2/M doubled, and the S phase decreased by half for cells 
expressing GFP-M2-APC compared to the untransfected control cells or cells expressing only 
GFP. Values for G0/G1, S, and G2/M, respectively are: 35.6% +/- 2.1, 40.9% +/- 2.4, 23.5% +/- 
3.3 (for Untransfected); 37.7% +/- 1.3, 41.0% +/- 9.6, 21.3% +/- 8.5 (for GFP); and 28.0% +/- 5.6, 
18.1% +/- 5.6, 53.9% +/- 8.9 (for M2-APC). For each transfection, 15,000 GFP-positive cells 
were analyzed. (C) Mitotic events assessed following DAPI staining. One hundred randomly 
chosen M2-APC- or GFP-expressing cells were analyzed from three independent experiments at 
24, 48 and 72 hours post transfection. None of the M2-APC-expressing cells appeared mitotic. A 
small number of the GFP-expressing cells were mitotic. (D) Representative immunofluorescence 
confocal microscopy of mitotic marker phospho-histone H3 from three independent experiments. 
No M2-APC-expressing cells were positive for phospho-histone H3, whereas a few 
GFP-expressing cells were positive. Arrow head indicates a cell that is positive for both GFP and 
phospho-histone H3. Bar, 10 μm. 
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The 15-amino acid repeat region of APC interacts with topo IIα 
Our original identification of APC in complex with topo IIα, an essential regulator of 
the G2/M transition prompted us to examine whether M2-APC could interact with topo 
IIα and possibly mediate the G2 arrest through this interaction. HCT116βw cells 
transfection and normalized against both pRL-TK Renilla activity and FOP-flash reporter 
activity. Values are mean s.d. for triplicate samples from a representative experiment. 
transiently expressing M2-APC had increased levels of total topo IIα (Figure 2.6A) and 
the topo IIα co-precipitated with GFP-M2-APC (Figure 2.6B).  In contrast, no topo IIα 
precipitated with the GFP in cells expressing GFP alone.  Because M2-APC and topo 
IIα interact, it is possible that M2-APC can influence the activity of topo IIα.  To test 
this directly, in vitro DNA relaxation and decatenation assays were performed using 
purified recombinant proteins topo IIα and M2-APC.  Purified M2-APC stimulated topo 
IIα activity in both DNA relaxation (Figure 2.6 C) and decatenation assays (data not 
shown).  This enhancement was apparent when purified M2-APC was provided at equal 
molar concentration to the topo IIα and was further pronounced with four times more 
M2-APC in the reaction (Figure 2.6C).  In the absence of topo IIα, purified M2-APC 
did not relax the DNA (Figure 2.6C) or bind to the DNA slowing its migration (data not 
shown).  Using a higher concentration of recombinant topo IIα, M2-APC still enhanced 
topo IIα activity (Figure 2.6D).  In contrast, BSA protein at an equal molar ratio slightly 
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Figure 2.5 
Expression of the 15-amino acid repeat region of APC does not alter β-catenin expression or 
localization. (A) Confocal immunofluorescence microscopy reveals similar β-catenin localization 
in M2-APC- and GFP-expressing HCT116βw cells. Note, nucleus (right panel) is abnormal in 
M2-APC-expressing cell. Bar, 5 μm. (B) Less than 1% of the total β-catenin 
co-immunoprecipitated with GFP-M2-APC using a GFP antibody (M2) and none 
co-immunoprecipitated with GFP alone (GFP). 10% input is 25 μg total protein. Transfection 
efficiency was ~50%. (C)  Nearly 10% of the total β-catenin co-immunoprecipitated with 
endogenous APC.  10% input is 30 μg total protein. Representative blots from five independent 
experiments. (D) Western blot reveals comparable levels of total β-catenin in M2-APC- (M2) and 
GFP-expressing (GFP) cells. Equivalent amounts of total protein from whole cell lysates were 
loaded. (B, D) Representative blots from three independent experiments. (E) Cells were 
cotransfected with GFP-M2-APC or GFP, SuperTOP-flash or FOP-flash reporters, and pRL-TK 
Renilla luciferase plasmid. Luciferase activities were determined 24 hours post transfection and 
normalized against both pRK-TK Renilla activity and FOP-flash reporter activity. Values are 
mean ±s.d. for triplicate samples from a representative experiment. 
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Figure 2.6 
The 15-amino acid repeat region of APC associates with topo IIa and enhances topo IIa 
activity. (A) Increased expression of topo IIa in M2-APC-expressing cells compared to 
GFP-expressing cells. Equivalent total protein loaded in each lane. (B) Topo IIa co-
immunoprecipitates with M2-APC, but not with GFP. 10% input is 25 mg total protein. 
(*) marks migration of the antibody heavy chain. (A, B) Representative blots from five 
independent experiments. (C, D) Representative topo IIa DNA relaxation assays from 
five independent experiments. R, relaxed plasmid DNA; S, supercoiled plasmid..  (C) 
Purified recombinant human topo IIa (0.35 mM) slightly relaxed supercoiled plasmid 
DNA (lane 2).  Addition of purified recombinant M2-APC (0.35 or 1.75 mM) to the 
reaction resulted in progressively enhanced topo IIa plasmid relaxation activity (lane 
3 and 4).  M2-APC did not have plasmid relaxation activity in the absence of topo IIa 
(lane 5). (D) Using a higher concentration of topo IIa (0.7 mM), the addition of BSA 
(0.7 mM) did not enhance the plasmid relaxation activity, but rather slightly inhibited it 
(compare lanes 2 and 3).  M2-APC (0.7 mM) enhanced the plasmid relaxation activity 
(lane 5).
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inhibited topo IIα activity (Figure 2.6D).  These in vitro assays provide additional 
support for a functional interaction between APC and topo IIα.  Taken together, our 
data implicate topo IIα as a mediator of abnormal DNA morphology and G2 arrest 
associated with exogenous M2-APC expression.  
Discussion 
In this paper we identify a novel interaction between the tumor suppressor protein 
APC and topo IIα.  This interaction was demonstrated by colocalization, reciprocal 
co-immunoprecipitation, FRET, and functional assays.  Topo IIα interacts with the 
15-amino acid repeat region of APC (M2-APC, amino acid 959-1338).  When 
over-expressed in colon cancer cell lines, M2-APC located predominantly to the nucleus.  
Cells expressing M2-APC displayed abnormal nuclear morphology and were inhibited in 
the G2 phase of the cell cycle.  Although M2-APC could bind β-catenin, we found no 
evidence supporting a role for β-catenin in the observed phenotypes.  Our data suggest a 
novel role for nuclear APC in the regulation of cell cycle progression, potentially through 
an interaction between topo IIα and the 15 amino acid repeat region of APC.  
The GFP-M2-APC protein was not expected to locate predominantly to the nucleus.  
Although endogenous full length APC exists in both cytoplasm and nucleus (20, 30), the 
classic NLSs that are thought to facilitate nuclear localization of APC (28) are not present 
 75
in the M2-APC fragment. The M2-APC region is retained in most truncated forms of 
APC associated with colorectal cancer and these truncated APC proteins are capable of 
nucleo-cytoplasmic shuttling (31). However, the nuclear import ability of these truncated 
APC proteins has been attributed to the armadillo repeat region (aa 334-625), not the 15 
amino acid repeat region (32). With an estimated molecular weight of ~70 kDa, 
GFP-M2-APC is too large to enter the nucleus by diffusion which has a size limitation of 
30-50 kDa (33-35). Therefore, M2-APC likely contains a nonstandard NLS or is carried 
into the nucleus by a nuclear binding partner. Because here we show that M2-APC binds 
to the abundant nuclear protein topo IIα, it is possible that nuclear entry of M2-APC is 
facilitated in part by topo IIα. APC has also been reported to bind Proliferating Cell 
Nuclear Antigen (PCNA) through the M2 region (36) and we have confirmed that PCNA 
co-immunoprecipitates with M2-APC (data not shown). We reason that other nuclear 
proteins, such as PCNA, might contribute to the nuclear entry of M2-APC as well.  
As an abundant nuclear protein, topo IIα is involved in a number of processes 
throughout the cell cycle, including transcription, DNA replication, chromatin 
recombination and organization, and regulation of the G2 decatenation checkpoint (9, 
11-15).  It is possible that the topo IIα we consistently found associated with 
endogenous APC and with the M2-APC fragment (Figure 2.1B & 2.6B) corresponds to a 
specific pool of topo IIα involved in regulation of the G2-M transition. Other pools of 
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topo IIα might be positioned near replicating heterochromatin during S phase (37), 
tightly associated with DNA to aid chromosome assembly at the G2-M transition (38-40), 
responsible for transcription regulation at G1/S (41), or involved in chromosome 
segregation at the exit of mitosis (16, 42, 43).  One explanation for the rather modest 
amount of topo IIα that co-precipitated with endogenous APC is that the interaction 
between APC and topo IIα is transient, only occurring at a specific point of the cell cycle.   
APC is not the first tumor suppressor protein to interact with topo IIα.  BRCA1 (44, 
45), RB (46), and p53 (47) each bind to topo IIα and thereby effect topo IIα functions.  
A recent report also links topo IIα to the oncoprotein β-catenin and its transcription 
co-factor TCF (41).  Over-expression of topo IIα led to enhanced β-catenin /TCF 
transcription activity, while expression of a constitutively active β-catenin led to 
increased topo IIα activity measured in a whole cell lysate.  We predict that β-catenin 
/TCF associates with a topo IIα pool that is involved in transcription regulation at G1/S.  
It is possible that this interaction is indirect and mediated by APC.  APC has been found 
in association with the enhancer region of genes regulated by β-catenin/TCF (48).  In 
contrast, we suspect that the APC/topo IIα interaction we described here is direct.  
Purified recombinant human M2-APC enhanced the plasmid relaxation activity of 
purified topo IIα in our in vitro assays which lacked other potential linker proteins 
(Figure 2.6, C and D).  Moreover, M2-APC does not appear to bind directly to DNA as 
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determined by gel shift assays (data not shown).  We propose that the pool of topo IIα 
that interacts with APC to impact G2 cell cycle transition is separate from the pool 
involved in β-catenin mediated transcription.  
We report that the topo IIα protein level was higher in cells expressing 
GFP-M2-APC than in GFP-expressing cells (Figure 2.6A).  This observation is 
consistent with previous reports that topo IIα levels peak in G2 (49).  We also report 
that purified M2-APC enhances topo IIα activity in an in vitro relaxation assay (Figure 
2.6C and D).  Cell cycle progression from G2 to M is likely dependent on the 
maintenance of topo IIα activity at a precise level.  Indeed, Epstein-Barr Virus kinase 
BGLF4 both stimulates topo IIα activity and induces premature chromosome 
condensation similar to the abnormal DNA morphology we report with M2-APC 
expression (50). Furthermore, protein kinase C δ regulates topo IIα activity specifically 
during S-phase with aberrant activation of topo IIα by protein kinase C δ leading to 
apoptosis (51).  At the simplest level, we propose that endogenous APC regulates topo 
IIα activity and thereby facilitates G2-M cell cycle progression.  
Topo IIα activity is essential for the chromatin decatenation required before mitosis 
(16).  APC locates near centrosomes during early and late stages of mitosis and has also 
been implicated in maintenance of chromatin structure (5, 41). Therefore, we cannot 
exclude the possibility that both APC and topo IIα provide multiple functions throughout 
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the G2/M transition.  We propose that a functional interaction between APC and topo 
IIα results in regulation of topo IIα activity.  Without this regulation, cell cycle 
progression would be affected. Given that truncated APC found in most colorectal 
cancers includes the M2-APC region, it is possible that topo IIα regulation is maintained 
in these cancers. In this scenario, retention of the topo IIα regulatory domain in truncated 
APC might be essential for cell viability. Alternatively, truncated APC proteins 
associated with cancer might behave more like the M2-APC fragment and be unable to 
effectively regulate topo IIα activity. The resulting stimulation of DNA cleavage by topo 
IIα would be predicted to induce chromosome instability, a hallmark of cancer. 
Taken together, we propose a novel function for the tumor suppressor APC in 
regulation of the G2-M cell cycle transition, potentially through interaction with topo IIα. 
Future investigation will be needed to determine the precise underlying mechanism by 
which M2-APC promotes G2 cell cycle arrest.  Such studies will potentially reveal a 
novel activity of APC in tumor suppression. This expanded role of the tumor suppressor 
APC has obvious implications in explaining the deregulation of topo IIα in colon cancer 
tissue (17) and for the use of topo IIα inhibitors as chemotherapeutic agents to treat 
colorectal cancer.  
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CHAPTER 3 
CENTRAL DOMAINS OF ADENOMATOUS POLYPOSIS COLI INHIBIT 
ENDOGENOUS TOPOISOMERASE IIα ACTIVITY AND ARREST CELLS IN G2 
Abstract 
 Tumor suppressor Adenomatous Polyposis Coli (APC) is a multi-functional protein.  
Mutations in APC are thought to initiate the majority of colorectal cancers. Our previous 
investigation implicated the 15 amino acid repeat region of APC (M2-APC) in the 
regulation of the G2-M cell cycle transition through interaction with topoisomerase IIα 
(topo IIα). We now demonstrate that the 20 amino acid repeat region of APC (M3-APC) 
also interacts with topo IIα. Expression of M3-APC in cultured colonic cells causes cell 
accumulation in G2, similar to expression of M2-APC. However, in cells with reduced 
endogenous topo IIα, expression of either M2- or M3-APC does not result in G2 arrest.  
Therefore, the ability of M2- and M3-APC to induce G2 arrest appears dependent on 
normal expression of topo IIα. Expression of M2- or M3-APC in cultured cells leads to 
reduced activity of endogenous topo IIα. This finding is consistent with previous reports 
that inhibition of topo IIα activates the G2 decatenation checkpoint, leading to G2 cell 
cycle arrest. Although both central domains of APC are also involved in 
down-regulation of β-catenin, this G2 cell cycle arrest appears to be independent of 
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β-catenin. Together, our data establish that two central APC domains interact with topo 
IIα, inhibit topo IIα decatenation activity, and cause G2 cell cycle arrest. These findings 
implicate APC in regulation of the G2 decatenation checkpoint.  
Introduction 
Adenomatous Polyposis coli (APC) is an established tumor suppressor protein. 
Mutation of the APC gene is considered an initiating event in over 80% of all colorectal 
cancers (1).  The ability of APC to suppress Wnt signaling by targeting β-catenin for 
ubiquitin-mediated proteasomal degradation is considered critical for APC to suppress 
tumorigenesis (2-6). Although alteration of either APC or β-catenin is sufficient for 
initiating intestinal tumors, APC likely suppresses tumor development through pathways 
besides inhibiting Wnt signaling [see review (7)].  
Among the multiple functions of APC that have been identified are spindle formation 
and microtubule stabilization (8-11), long patch base excision repair (12), and cell cycle 
regulation (8, 13-18). Mutations in APC have also been implicated in chromosomal 
instability and aneuploidy in early FAP polyps (19-21). The function of APC, as well as 
the underlying mechanism for many of these processes, is only beginning to be 
understood.  
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Recently, we have identified topoisomerase IIα (topo IIα) as a novel APC binding 
partner that participates in regulation of the G2-M cell cycle transition (22).  Topo IIα is 
a type II topoisomerase that catalyzes DNA topology change throughout the cell cycle 
(23-26). Topo IIα has also been considered a critical regulator at the G2/M decatenation 
checkpoint during cell division (27). Inhibition of topo IIα activity leads to activation of 
the G2 decatenation checkpoint resulting in G2 arrest (27). Topo IIβ with similar activity 
as topo IIα, is believed to be dispensable in cell cycle control because topo IIβ-null cell 
lines remain viable (28-30).  
Previously, we found endogenous APC interacted with topo IIα but not with topo 
IIβ.  Expression of a central fragment of APC that binds topo IIα led to abnormal nuclear 
morphology and cell cycle inhibition in G2 in various colon cancer cells lines (22). 
Although β-catenin is capable of binding to this central fragment of APC, β-catenin 
appeared not involved in this process. We concluded that nuclear APC interacts with topo 
IIα and thus might be involved in the regulation of cell cycle progression. 
In the current study, we identify a second domain in the central portion of APC that 
specifically binds to topo IIα but not topo IIβ. Both APC central domains dramatically 
impact the activity of topo IIα in vitro and in vivo. Expressing each of the APC domains 
capable of topo IIα interaction leads to cell cycle arrest in G2. Using the HL-60/MX2 cell 
line, a variant of human promyelocytic leukemia cell line HL-60 with notably reduced 
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levels of topo IIα, we demonstrate that APC-mediated cell cycle arrest happens only in 
cells with normal expression of endogenous topo IIα. Our data suggest APC participates 
in the topo IIα-dependent regulation of the G2-M transition.  
Materials and Methods 
Cell culture and DNA constructs 
 HCT116βw cells (a generous gift from Dr. Bert Vogelstein) were grown in McCoy’s 
5A medium (Gibco) supplemented with 10% FBS (Hyclone). HL60 cells (ATCC) were 
grown in Iscove's Modified Dulbecco's Medium (ATCC) supplemented with 20% FBS 
(Hyclone). HL60/MX2 (ATCC) were grown in RPMI 1640 media (Cellgro) 
supplemented with 10% FBS. Expression constructs for APC fragments fused to GFP 
were kindly provided by Dr. Naoki Watanabe and have been described previously (9). 
His and S dual-tag fused M2-APC was made as described (22). To generate recombinant 
N-terminal His and S dual-tag fused APC fragment M3, the corresponding cDNA for 
APC (amino acid 1327-2058) was amplified using PCR and subcloned into a pET-30a(+) 
vector. 
 87
Immunoprecipitation and immunoblots 
 HCT116βw cells were transfected using Lipofectamine2000 reagent according 
to the manufacturer's protocol (Invitrogen). Immunoprecipitation (IP) and immunoblots 
(IB) were performed using anti-GFP pAb (Invitrogen) as described (22). Immunoblots 
were probed with the following antibodies: anti-β-catenin (1:2000, Sigma), anti-topo 
IIα (1:1000, Research Diagnostics, Inc.), anti-topo IIβ (1:1000, Santa Cruz), anti-GFP 
pAb (1:1000, Invitrogen) and anti-α-tubulin (1:2000, Oncogene).    
Electroporation and FACS analysis 
 Cells grown on plastic were treated with trypsin to obtain a single cell suspension. A 
total of 2μg of GFP, GFP fused M2-, or M3-APC plasmid were electroporated using 
Nucleofector I (Amaxa) according to the manufacturer's protocol. Electroporation 
programs used are: HCT116βw (program D-32), HL60 (program T19), and HL60/MX2 
(program X-03). 48hrs post transfection, single cells in suspension were stained with 
0.5μg/ml Hoechst 33342 (Invitrogen) for 30min at 37℃. FACS analysis was performed 
using both UV and 488nm lasers on a 5-laser BD LSRII flow cytometry (BD Bioscience). 
10,000 GFP-positive cells were collected for each sample. Data were analyzed using BD 
FACSDiva Software (BD Bioscience) and plotted using WinMDI 2.9.  
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Recombinant proteins and topo IIα decatenation assays  
Recombinant S-tag fused M2- and M3-APC were generated as described (22). BSA 
(Sigma) was diluted in S-tagged APC protein dilution buffer (20mM Hepes pH 7.8, 
100mM NaCl). Recombinant human topo IIα and topo IIβ were made as described (31, 
32). In vitro topo IIα decatenation assays were performed as described (24). Nuclear 
extracts were made exactly as previously described (33). Nuclear extracts were frozen 
and kept in aliquots in liquid nitrogen if not immediately used after preparation. 
Immunoblots were performed first to normalize topo IIα protein levels in all nuclear 
extracts. Then ~1μg of nuclear extract with normalized topo IIα protein level was used 
for decatenation activity assays.  
Antibodies and immunofluorescence 
Cells transfected with GFP or GFP-fused M3-APC were fixed with 4% 
Paraformaldehyde, and immunostaining was performed using anti-phospho-histone H3 
(1:500, Upstate) as described (34).  100 GFP-positive cells were randomly chosen, and 
only cells also positive for phospho-histone-H3 were counted. The number of mitotic 
cells was calculated as an average ± s.d. of three independent experiments.  
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Results 
A central domain of APC capable of β-catenin down-regulation also binds topo IIα 
As a critical tumor suppressor in the colon, APC has been widely studied, and 
multiple APC functions have been identified in different stages of the cell cycle [see 
review (35)].  Previously, we found full-length endogenous APC specifically interacts 
with topo IIα and expression of the 15 amino acid repeat region of APC (M2-APC) that 
interacts with topo IIα results in altered DNA morphology and accumulation of cells in 
the G2 phase (22). For this prior analysis, technical difficulties in protein expression and 
purification limited the domains of APC that were characterized in full.  
In the present study, we report that both M2-APC and the 20 amino acid repeat 
region of APC (M3-APC) interact with topo IIα. Topo IIα specifically co-precipitates 
with both GFP-fused M2- and M3-APC (Figure 3.1, top blot). However, topo IIβ does 
not co-precipitate with either APC fragment under the same experimental conditions 
(Figure 3.1, second blot). M2-APC encompasses APC amino acids 959-1338 while 
M3-APC contains amino acids 1211-2075. These two regions together comprise the 
entire 15 amino acid and 20 amino acid repeat regions of APC, respectively, which 
mediate β-catenin binding and downregulation. Not surprisingly, β-catenin 
co-precipitated with both M2- and M3-APC (Figure 3.1, third blot).   
Figure 3.1 
Both 15aa and 20aa repeat regions of APC interact with topo IIa. Topo IIa co-
immunoprecipitates with both M2-APC and M3-APC, but not with GFP from M2- or 
M3-APC or GFP expressing HCT116bw cells. 10% input equals 10 mg total protein. 
Topo IIa does not co-precipitate with M2- or M3-APC, whereas b-catenin does.  Blots 
probed for a-tubulin served as a loading control for the input samples and a negative 
control for the immunoprecipitations.  (*) marks migration of antibody heavy chain. 
Representative blots from three independent experiments are shown.
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Expression of M2- or M3-APC results in G2 cell cycle arrest 
Like M2-APC (22), M3-APC binds topo IIα in cells (Figure 3.1). Thus, we 
expressed M3-APC in HCT116βw cells to examine if M3-APC also caused a delay in the 
cell cycle. As predicted, cells expressing M3-APC as well as M2-APC progressively 
accumulate in the G2/M phases of the cell cycle, compared to cells expressing GFP only 
(Figure 3.2 A and B, Table 3.1). By 72 hours, cells expressing M3-APC displayed a 
2-fold increase in the G2/M population and a 31% reduction in the S phase population, 
while cells expressing M2-APC displayed a 2.4-fold increase in the G2/M population and 
a 77% reduction in the S phase population, compared to GFP expressing cells. Overall, 
expression of M2- or M3-APC consistently led to cell cycle arrest in G2/M. Of note, the 
reduction in S phase cells seen upon expression of M2-APC and to a lesser extent 
M3-APC, suggested a second cell cycle delay prior to S phase, likely in G1. This 
apparent delay in G1 is consistent with a previous observation that APC controls the 
G1-S transition (15). M2-APC expression elicits G2 phase cell cycle arrest rather than 
arrest in M (22). The percentage of M3-APC expressing cells undergoing mitosis (4%), 
as indicated by phospho-histone H3 positive staining, is similar (p>0.05) to that in 
GFP-expressing cells (3%) (Figure 3.3 A and B). Therefore, as previously reported for 
M2-APC, the expanded G2/M population of M3-APC expressing cells determined by  
Figure 3.2 
Cells expressing M2- or M3-APC progressively accumulate in G2/M. (A) Histograms show-
ing representative FACS displays of cell cycle distribution assessed by Hoechst blue staining 
at 24, 48, and 72hrs post-transfection with expression constructs for GFP fused M2-, M3-APC, 
or GFP. Only GFP positive cells are displayed. (B) Bar graphs show FACS based cell cycle 
distribution at 3 timepoints post transfection from three independent experiments. By 72hrs 
post-transfection, the fraction of M2-APC and M3-APC expressing cells in G2/M increased by 
2.4-fold and 2-fold, respectively; and the S phase decreased by 77% and 31% , respectively.
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Figure 3.3
Cells expressing M3-APC exhibit normal M phase cell cycle distribution. (A) Cells 
expressing GFP or GFP-M3-APC were analyzed for expression of mitotic marker phos-
pho-histone H3. A small portion of GFP-expressing cells shown were double positive for 
phospho-histone H3. (B) Scoring 100 GFP-positive cells from each of three independent 
experiments revealed no change in the mitotic population when cells expressed M3-APC. 
Bar, 10 mm.
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Table 3.1 Cell cycle distribution in cells expressing GFP, M2-APC, or M3-APC  
 
 24 h G0/G1 (%) S (%) G2/M (%) Aneuploid 
GFP 44.3 +/- 4.7 33.4 +/- 1.3 22.3 +/- 4.8 1.7 +/- 1.21 
M2-GFP 44.1 +/- 1.7 27.9 +/- 1.6 28.0 +/- 2.8 2.8 +/- 0.5 24hrs 
M3-GFP 41.5 +/- 4.6 31.0 +/- 1.6 27.5 +/- 3.1 2.6 +/- 0.6 
GFP 43.8 +/- 2.8 34.5 +/- 4.3 21.7 +/- 3.3 1.5 +/- 0.8 
M2-GFP 43.3 +/- 5.4 20.6 +/- 0.6 36.1 +/- 5.9 5.5 +/- 1.1 48hrs 
M3-GFP 43.9 +/- 3.5 23.2 +/- 2.9 32.9 +/- 1.6 4.1 +/- 0.7 
GFP 41.1 +/- 2.8 39.7 +/- 3.4 19.2 +/- 3.4 1.7 +/- 0.8 
M2-GFP 43.1 +/- 6.9 9.2 +/- 6.6 47.7 +/- 2.5 9.0 +/- 4.9 72hrs 
M3-GFP 33.6 +/- 9.5 27.2 +/- 6.6 39.2 +/- 3.0 5.6 +/- 3.0 
 
Transfected cells were stained with Hoechst blue, and the cell cycle distribution G0/G1 (2N), S 
(between 2N and 4N), and G2/M (4N) was determined by FACS at three time points post 
transfection. Aneuploid cells are shown as a percentage of the total cycling cell populations. For 
each transfection, 10,000 GFP-positive cells were analyzed by FACScan. Table shows the 
average from three independent experiments. 
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FACS analysis represents an arrest in G2. Together, these results demonstrate that 
M3-APC and M2-APC are each capable of inducing G2 cell cycle arrest when expressed 
in colon epithelial cells. 
Cells with reduced topo IIα  levels do not arrest in G2 following expression of either M2- 
or M3-APC  
 Based on our data, we propose a model whereby exogenous M2- or M3-APC 
interacts with endogenous topo IIα resulting in G2 cell cycle arrest.  Ideally, in order to 
show this APC-mediated cell cycle perturbation is dependent upon topo IIα, we should 
eliminate topo IIα from the analyzed cells. Unfortunately, topo IIα is an essential protein 
throughout the cell cycle, and perturbation of its activity typically results in inhibition of 
normal cell proliferation. No cultured mammalian cell line completely lacking topo IIα 
has been reported in the literature. In a cell line in which topo IIα can be conditionally 
deleted, complete removal of topo IIα leads to acute cell cycle delay in G2 followed by 
cell death (36). However, there are cell line variants with greatly reduced topo IIα levels 
which are comparatively resistant to topo II targeting drugs. HL-60/MX2 cells, a variant 
of the human promyelocytic leukemia cell line HL-60, were selected for resistance to the 
topo II inhibitor mitoxantrone (37). HL-60/MX2 cells express truncated topo IIα with 
reduced activity and at a reduced level compared to the parental HL-60 cells (38-40) 
Figure 3.4 
Expression of M2- or M3-APC causes G2/M accumulation in HL60 but not HL60/MX2 cells 
with reduced topo IIa. (A) Cell cycle distribution of HL-60 and HL-60/MX2 cells expressing 
M2- or M3-APC. (B) Detailed bar graph showing only G2/M population from both cells lines 
in (A). Parental HL60 cells exhibit a 1.9 fold increase in G2/M when expressing M2-APC (*,p= 
0.02) and a 3.4 fold increase when expressing M3-APC (**, p=0.02), compared to cells express-
ing only GFP. HL60/MX2 cells do not accumulate in G2/M when expressing M2- (#, p=0.09) or 
M3-APC (##, p=0.06), compared to cells expressing only GFP. For both cell lines, 10,000 GFP-
positive cells were analyzed from three independent experiments at 48hrs post transfection.
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Table 3.2 Cell cycle distribution of parental HL60 and HL60/MX2 cells expressing GFP, 
M2-APC, or M3-APC 
 
HL60 G0/G1 (%) S (%) G2/M (%) 
GFP 81.8 +/- 5.4 13.0 +/- 3.8 5.2 +/- 2.0 
M2-GFP 82.2 +/- 7.8 7.8 +/- 6.8 10 +/- 2.1 
M3-GFP 67.3 +/- 4.1 14.8 +/- 5.1 17.9 +/- 3.3 
 
HL60/MX2 G0/G1 (%) S (%) G2/M (%) 
GFP 65.7 +/- 1.0 21.7 +/- 1.8 12.6 +/- 1.0 
M2-GFP 53.3 +/- 15.9 39.4 +/- 14.2 7.3 +/- 4.0 
M3-GFP 50.5 +/- 9.7 42.3 +/- 10.1 7.2 +/- 2.8 
 
Cell cycle distributions were determined by FACS analysis of Hoechst blue stained GFP, M2- 
and M3-APC expressing cells at 48 hrs post transfection. For each transfection, 10,000 
GFP-positive cells were analyzed by FACS. Table shows the average from three independent 
experiments. 
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 and almost no topo IIβ.  When M2- or M3-APC was expressed in parental HL-60 cells, 
the G2/M population increased significantly (Figure 3.4 A left graph and B, Table 3.2). 
M2-APC expression resulted in nearly a doubling of the G2/M population, while 
M3-APC expression resulted in tripling of the G2/M population. The G2 arrest in HL-60 
cells indicates that the impact of M2- and M3-APC on the cell cycle is not restricted to 
colon epithelial cell lines. HL-60 cells grow in suspension and divide less frequently than 
the colon epithelial cells. Thus, it was not surprising to find the majority of cells in the 
G0/G1 phases of the cell cycle. In contrast, HL-60/MX2 cells expressing M2- or 
M3-APC showed no increase in the G2/M population (Fig. 3.4 A right graph and B, 
Table 3.2). Rather, the slight decrease in G2/M and increase in the S population of M2- 
and M3-APC expressing cells was not significantly different from the GFP-expressing 
HL-60/MX2 cells (p>0.05). Taken together with our observation that M2- and M3-APC 
interact preferentially with topo IIα rather than topo IIβ (Figure 3.1), we propose that cell 
cycle arrest in cells expressing M2- and M3-APC is dependent on normal expression of 
topo IIα.   
Expression of M2- or M3-APC inhibits topo IIα activity in cells 
 Inactivation of topo IIα leads to G2 cell cycle arrest, most likely by activating the G2 
checkpoint (27). To examine if the G2 cell cycle delay caused by M2- or M3-APC 
expression resembled activation of the G2 checkpoint, we extracted M2- or M3-APC 
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expressing HCT116βw cell nuclear lysates containing topo IIα to assess the activity of 
endogenous topo IIα. Topo IIα protein levels were used to standardize the amount of 
each nuclear extract tested in DNA decatenation assays (Fig. 3.5 B, top blot). Nuclear 
lysates from HCT116βw cells expressing GFP had similar topo II decatenation activity as 
lysates from non-transfected HCT116βw cells (Fig. 3.5 A, lanes 3 and 4). Nuclear 
extracts from cells expressing M2- and M3-APC exhibited reduced topo II decatenation 
activities compared to extracts from untransfected or GFP-expressing cells (Fig. 3.5 A, 
lanes 5 and 6). There was only minimal topo IIβ protein in the nuclear extracts, and this 
level did not correlate with the DNA decatenation activity of the samples (Fig. 3.5 B, 
middle blot). M2- and M3-APC were present in these nuclear lysates (Fig. 3.5 B, bottom 
blot). We conclude that this nuclear M2- or M3-APC is responsible for inhibition of 
endogenous topo IIα activity. 
Discussion 
In this study we identify a novel topo IIα binding domain (M3) in the central part of 
APC. Cells expressing M2- or M3-APC were inhibited in the G2 phase of the cell cycle. 
Endogenous topo IIα activity in both M2- or M3-APC expressing cells was greatly 
reduced. Although M3-APC could bind β-catenin, we found no evidence supporting a 
role for β-catenin in the observed phenotypes. Our data indicate the central region of 
APC interacts with and inhibits topo IIα, thus regulating G2-M cell cycle progression. 
Figure 3.5 
Exogenous expression of M2- or M3-APC inhibits topo II decatenation activity in nuclear 
extracts. (A) Nuclear extracts from HCT116bw cells (lane 3) or cells expressing GFP (lane 4) 
possess decatenation activity.  Recombinant purified human topo IIa provides a positive control 
(lane 2). Cells expressing M2- or M3-APC show reduced decatenation activity (lanes 4 and 5). 
One mg of total nuclear extract was used for each assay. Representative assays from three inde-
pendent experiments are shown. cat DNA, catenated kDNA; decat DNA, decatenated kDNA. (B) 
Immunoblots reveal comparable topo IIa protein in each nuclear extract used in (A) (top panel). 
Minimal topo IIb was detected on replicate blots (middle panel). GFP and GFP-fused M2-APC 
were abundant in the nuclear extracts (bottom panel). Full length GFP-M3-APC (~150kDa) 
was also present, along with multiple degradation products. Six mg of total nuclear extract were 
loaded in each lane. Representative blots from three independent experiments are shown.
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HCT116βw cells express full length endogenous APC as well as wild-type β-catenin.  
Since HCT116βw cells have been altered from the parental HCT116 line such that they 
no longer express the mutant β-catenin allele (encoding a stabilized version of β-catenin) 
and they do not have high endogenous β-catenin activity (41). That there is only a slight 
reduction in β-catenin activity in HCT116βw cells expressing M3-APC (data not shown) 
is likely because endogenous APC is already eliminating most of the β-catenin available 
for destruction. M2- and M3-APC both inhibit topo IIα activity and arrest cells in the G2 
phase, indicating their functional similarity in cell cycle modulation. The phenotype of 
G2 arrest caused by expression of M2-APC is independent of β-catenin (22). Therefore, it 
is likely that the nearly identical phenotype of G2 arrest caused by M3-APC expression 
also does not require β-catenin. 
Previously, we reported that purified recombinant M2-APC (amino acids 999-1326) 
stimulated the activity of purified topo IIα in plasmid relaxation and decatenation assays 
(22). Purified recombinant M3-APC (amino acids 1327-2058), which does not overlap 
with the purified M2-APC fragment, also enhanced the topo IIα decatenation activity in 
vitro (Figure 3.6 A). In contrast, we showed that expression of M2- or M3-APC in cells 
inhibits endogenous topo IIα activity in nuclear lysates (Figure 3.5 A). It is not obvious 
how to reconcile these two findings. Given the abundance of topo IIα in the soluble 
nuclear lysates (Figure 3.5 B), it appears that over-expressed M2- or M3-APC does not  
Figure 3.6 
Recombinant M2- and M3-APC enhance topo IIa activity in vitro. (A) Purified recombinant 
human topo IIa was used at a concentration (0.12 mM) which could slightly decatenate catDNA 
(lane 4).  Addition of increasing amounts (0.12, 0.24, and 0.6 mM) of purified recombinant M2-
APC (lanes 5-7) or M3-APC (lanes 8-10) resulted in progressively enhanced topo IIa activity. 
M2-, or M3-APC (0.6 mM) alone did not display any decatenation activity. (B) Using a higher 
concentration of topo IIa (0.18 mM), the addition of M2- or M3-APC (0.18 mM) also enhanced 
topo IIa activity. In contrast, negative control BSA (0.18 mM) did not enhance the activity of 
topo IIa, but rather slightly inhibited it (lanes 6-8). (C) Purified recombinant human topo IIb 
(0.018 mM) decatenates catDNA (lane 5). Addition of M2- or M3-APC (0.018 and 0.09 mM) 
minimally enhanced topo IIa activity (lanes 8-11). Addition of negative control BSA (0.018 
and 0.09 mM) results in no difference in topo IIa activity (lanes 6 and 7). BSA, M2-, or M3-
APC (0.09 mM) did not display any decatenation activity in the absence of topo IIa (lanes 2-4). 
(A-C) Representative assays from three independent experiments are shown. cat DNA, catenat-
ed kDNA; decat DNA, decatenated kDNA.
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reduce topo IIα activity simply by causing precipitation of topo IIα, thus rendering it 
insoluble. One possibility is related to conditions that promote DNA catenation verses 
decatenation. Proteins such as histones, that promote DNA condensation, shift the 
equilibrium from decatenation to catenation (42, 43).Since nuclear extracts may contain 
histones and histone-like proteins, the reduction of decatenated DNA seen in the topo IIα 
activity assay using nuclear extracts from cells expressing M2- and M3-APC might 
represent a re-catenation of the decatenated kinetoplast DNA (Figure 3.5A, lanes 5 and 6). 
However, substituting plasmid DNA for the kinetoplast DNA in the same assay did not 
result in DNA catenation, but rather, regular laddering of relaxed plasmid DNA (data not 
shown). Therefore, M2- or M3-APC expression does not appear to promote DNA 
condensation as a means to induce DNA catenation.  
After excluding the situations stated above, we were left with three possibilities.  
First, the differences observed using purified recombinant proteins versus the mammalian 
nuclear extracts might stem from the lack of post-translational modification of the 
purified components expressed in a non-mammalian (note: our topoisomerase IIα is 
expressed in yeast, not bacteria) system. Second, topo IIα modifications including 
SUMOylation, ubiquitination and phosphorylation are seen in cells (42-45). Although the 
exact functions of these modifications are not clear, it is possible that expression of M2- 
or M3-APC in cells modulates some of these post-translation modifications of topo IIα 
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and thus alters cellular topo IIα activity. Third, the complete composition of the APC- 
topo IIα complex has not been determined. Other APC-interacting proteins in this 
complex could potentially serve to inhibit topo IIα activity. Future analysis of full-length 
APC and its impact on topo IIα activity both in vivo and in vitro will help address this 
discrepancy. We predict that interaction of full length APC with topo IIα will result in 
inhibition of topo IIα activity in cells.  
Here we show that M2- and M3-APC interact with topo IIα but not topo IIβ in cells 
(Figure 3.1). This finding is consistent with our previous observation that full-length 
endogenous APC only interacts with topo IIα but not topo IIβ (22). Purified M2- and 
M3-APC each slightly elevated topo IIβ activity (Figure 3.6 C, lanes 8-11), an effect 
much less than with topo IIα.  In addition, it is possible that in a reconstituted system 
using high concentrations of purified components, M2- and M3-APC can interact with 
topo IIβ and thereby affect its activity. However, M2- and M3-APC do not complex with 
topo IIβ (Figure 3.1). Successful generations of cell lines and mouse models completely 
lacking topo IIβ (28-30) suggest that topo IIβ is dispensable for cell cycle progression.  
Thus, it appears that APC-mediated G2 cell cycle arrest is independent of topo IIβ. 
Topo IIα protein levels fluctuate during different stages of the cell cycle, peaking in 
G2 (46). However, the specific activity of topo IIα remains constant throughout the cell 
cycle (47-49). Thus, it is likely that the dramatic reduction in topo IIα activity in M2- or 
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M3-APC expressing cells did not result from changes in the specific activity of topo IIα. 
Rather, we propose that expression of M2- or M3-APC leads to inhibition of topo IIα 
activity, which causes G2 arrest. A variety of topo II inhibitors have been shown to delay 
cells in G2 by activating the G2 decatenation checkpoint (27). It is possible that the M2- 
and M3-APC fragments, and even full-length APC, serve to activate the G2 decatenation 
checkpoint by inhibiting topo IIα. The G2 decatenation checkpoint is vital for cell cycle 
control and genomic integrity. Cells lacking the G2 decatenation checkpoint become 
aneuploid (50, 51).  In our study, the population of aneuploid cells expressing M2- or 
M3-APC steadily increased from 24 to 72 hrs post-transfection (Table 3.1). This 
accumulation of aneuploid cells possibly results from inhibiting topo IIα activity in the 
small percentage of mitotic cells that escape the G2 decatenation checkpoint.  
As a critical component of the G2 decatenation checkpoint, topo IIα is important for 
regulation of normal cell proliferation (25, 52). If full length APC acts in a similar 
manner as the M2- and M3-APC fragments, it would be expected to inhibit topo IIα 
activity under physiological conditions to suppress tumor growth.  In cancer, mutant 
APC would fail to regulate this process and allow cells to escape the G2 checkpoint, 
accumulate chromosomal instability, and potentially become aneuploid. Over 60% of 
FAP polyps displayed aneuploidy (19-21), and mutations in APC have been shown to 
promote aneuploidy in mouse models as well (53, 54). Our results provide a potential 
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explanation for the presence of aneuploidy in early FAP and APC-driven mouse intestinal 
adenomas. Further studies are required to elucidate the mechanism of APC in topo 
IIα-dependent G2 checkpoint. These studies will increase our understanding of the 
molecular factors involved in the pathogenesis of colorectal cancer so that improved 
diagnostic and treatment strategies can be developed. 
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CHAPTER 4  
NOVEL ASSOCIATION OF APC WITH INTERMEDIATE FILAMENTS  
IDENTIFIED USING A NEW VERSATILE APC ANTIBODY 
Abstract 
Recognized as a key player in suppression of colon tumorigenesis, Adenomatous 
Polyposis Coli (APC) protein has been widely studied to determine its normal cellular 
functions. Direct interactions of APC with microtubule component tubulin and 
microtubule-binding protein EB1 point to a role for APC in spindle formation and 
migration. Recent studies have shown that APC regulates cell polarity and migration 
through interactions with the actin cytoskeleton. Therefore, it is of interest to determine if 
APC also interacts with the third cytoskeletal element: intermediate filaments. In recent 
years, however, inconsistencies of commercially available APC antibodies have limited 
the exploration of APC’s biological functions. Using a novel APC antibody raised against 
the 15 amino acid repeat region of APC (APC-M2), we immunoprecipitated endogenous 
wild-type APC and its binding proteins from HCT116βw cells, which contain wild-type 
APC and β-catenin. By Liquid Chromatography Tandem Mass Spectrometry 
(LC-MS/MS), we identified 42 proteins in complex with APC. Among the most abundant 
proteins found to interact with APC were β-catenin and intermediate filament (IF) 
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proteins lamin B1 and keratin 81. Association of lamin B1 with APC in both cultured 
cells and human colonic tissue was confirmed by co-immunoprecipitation and 
colocalization. APC also colocalized with keratins and remained associated with IF 
proteins throughout a sequential extraction procedure. We also verified the reliability of 
the new versatile APC antibody in several applications including immunoprecipitation 
and immunofluorescence. Thus, we introduce a new APC antibody that is useful for 
immunostaining, immunoblotting and immunoprecipitation. Using this antibody, we 
present evidence for an interaction between APC and IFs, independent of actin 
microfilaments or microtubules. Our results indicate that APC associates with all three 
major components of the cytoskeleton, thus expanding APC roles in the regulation of 
cytoskeletal integrity.  
Introduction 
Mutation of the tumor suppressor Adenomatous Polyposis Coli (APC) is an early 
event in colorectal carcinogenesis. Numerous studies on the subcellular localizations and 
binding partners of APC have indicated a role for APC in a wide variety of cellular 
functions in normal cells.  The most well characterized function of APC is to inhibit 
Wnt signaling by forming a multi-protein complex which targets cytoplasmic β-catenin 
for destruction (1-3). More recently, APC has been implicated in the regulation of 
cytoskeletal integrity. 
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APC linkage with the actin network has been demonstrated by both direct interaction 
of APC with actin (4) and also actin-dependent membrane-localization of APC (5). 
Ectopic expression of APC (6), APC truncating mutations (7), and APC loss (6, 8) all 
resulted in aberrant cell migration. Identification of APC in a complex with IQGAP (9), a 
scaffolding protein that binds to growing microtubules and regulates actin filament 
elongation (10)，provided evidence for a role of APC in cell migration. Depletion of 
either APC or IQGAP1 inhibited actin polymerization and cell polarization (9). APC also 
positively affects a Rac-specific GEF, ASEF (11), and thereby activates Cdc42 (12). A 
truncated APC protein commonly found in colon cancer failed to activate ASEF, 
potentially contributing to tumor formation (12).  
APC interactions with the microtubule cytoskeleton have also been determined.  
Early localization studies identified APC at the plus ends of microtubules, thus 
implicating APC in cell migration (13, 14). The functional interaction of APC with the 
microtubule network is strengthened by the finding that APC directly interacts with 
tubulin (15, 16) and the microtubule-binding protein, EB1 (17). Depletion of APC was 
shown to destabilize microtubules and inhibit spindle formation and cellular protrusions, 
thus compromising cell migration (18).  
Actin-containing microfilaments, microtubules, and intermediate filaments (IFs), 
constitute the three main cytoskeletal elements that coordinate to regulate cell structure, 
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polarity and migration. IFs function as a scaffold to maintain cell and tissue integrity and 
defects in IF impact a number of diseases [see review (19)]. In the present study, we 
provide further evidence for the involvement of APC in the regulation of cytoskeletal 
structure through interaction with IFs. Using APC-specific polyclonal sera raised against 
the 15 amino acid repeat region of APC (referred to APC-M2 pAb), we identified 
interactions of APC with IF proteins lamin B1, lamin B2, keratin 81 and keratin 82.  We 
verified lamin B1 interaction with APC by co-immunoprecipitation as well as by 
immunofluorescence microscopy in both cultured cells and human colonic tissue. Nuclear 
lamins are type V IFs that form a spherical mesh lining the nuclear envelope, providing 
attachment sites for chromosomes and nuclear pores (20). Keratins are type I and II IFs 
that are predominantly found in epithelial cells, giving cells structural integrity so that 
they can withstand mechanical stress (21).  Identifying an interaction between APC and 
IFs expands our understanding of the role of APC in cytoskeletal regulation.   
Although APC expression and functions have been widely studied in basic research 
and in clinical settings, recent reports have raised questions about the accuracy and 
reliability of many commercially available antibodies (22, 23). Therefore, an APC 
antibody that accurately depicts levels and subcellular localizations of APC in cells and 
especially in tissues is extremely important. Our characterization of the APC-M2 pAb 
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validates its use in a variety of applications including detection of APC protein in mouse 
and human tissues.   
Materials and Methods 
Cell culture and tissue preparation 
 HCT116βw cells (a generous gift from Bert Vogelstein) were grown in McCoy’s 5A 
media (Gibco) supplemented with 10% Fetal bovine serum (FBS) (Hyclone).  SW480 
cells (ATCC) were grown in RPMI 1640 media (Cellgro) supplemented with 10% FBS.  
HCA46 cells (a generous gift from Ian Tomlinson) were grown in high glucose DMEM 
media (Gibco) supplemented with 10% FBS. 184A1 cells (a generous gift from Martha 
Stampfer) are an immortalized human mammary epithelial cell line (24), and were grown 
in MCDB 170 media (Clonetics) supplemented as described (25). Colon and ileum 
tissues were removed from an 8 week old male C57/BL6 mouse (Charles Rivers 
Laboratory) immediately after CO2 asphyxiation, rolled into “swiss rolls”, embedded in 
OCT medium (Sakura Finetek) and frozen in ethanol-dry ice. Surgical removed normal 
human colonic tissue was immediately embedded in OCT medium and frozen in 
ethanol-dry ice.  
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Antibodies, immunostaining and confocal microscopy 
Tissue cryosections or cultured cells were fixed in 4% paraformaldehyde in PBS. 
Immunostaining of fixed tissue cryosections and cultured cells were performed as 
described (26, 27). Antibodies used for immunostaining include APC-M2-pAb (1;1000), 
anti-APC (1:50, ab-7, Calbiochem), anti-β-catenin (1:200, Transduction Lab), anti-lamin 
B1 (1:50, Oncogene), anti-pan-keratin (1:50, Sigma), Rhodamine-phalloidin (1:500, 
Invitrogen), and mixture of mAbs of anti-α & β-tubulin (a generous gift from Dave Gard); 
secondary antibodies of goat anti-mouse IgG FITC (1:200, Molecular Probe), goat 
anti-mouse IgG Alexa 488 (1:1000, Molecular Probes), goat anti-rabbit IgG Alexa 568 
(1:500, Molecular Probes), and goat anti-mouse IgG Alexa 568 (1:500, Molecular 
Probes). DNA was labeled with Topro-3 (1:1000, Molecular Probes) or DAPI (1:1000, 
Molecular Probes). Negative controls included incubation with secondary antibody alone, 
or, for double labeling experiments, secondary antibody with primary antibody of 
opposing species (eg. Alexa488 anti-mouse IgG with APC-M2-pAb).  These negative 
controls resulted in only minimal signal. 
Immunostained cells or tissues were visualized using a PlanNeofluor 40X/1.3 oil 
objective on a Carl Zeiss Laser Scanning Miscroscope (LSM) 510. Images were analyzed 
using Zeiss LSM Image Browser Version 4.2. Images of human colon sections were 
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captured as 2(X) by 3(Y) sub-images and automatically reassembled as one montage 
image.  
Immunoprecipitation and immunoblots 
 Purified recombinant His-S-M2-APC was resolved on a 4-12% NUPAGE gel 
(Invitrogen) and stained using a Colloidal Blue Staining Kit (Invitrogen) according to 
manufacturer’s protocol. Immunoprecipitation (IP) and immunoblots (IB) were 
performed using modified standard protocols. Cells at 90% confluency were lysed in 
buffer containing 50 mM Tris (pH 7.5), 0.1% NP-40, 100 mM NaCl, 1 mM MgCl2, 5 
mM EDTA, protease inhibitor cocktail (Sigma) and Halt phosphatase inhibitor cocktail 
(PIERCE) on ice for 30 minutes. Cell lysates were sonicated for 10 pulses at level 1 with 
10% output, 3 times using an ultrasonic homogenizer (Branson Sonifier 450). Soluble 
lysates were obtained by centrifugation at 17,000 x g for 20 min at 4oC. Specific 
antibodies were first pre-incubated with Protein-A dynabeads (Invitrogen) for 2 hours at 
room temperature. Then antibody saturated dynabeads were washed with 0.2 M 
Triethanol amine (pH 8.0) twice and crosslinked using 4 mM DMP (PIERCE) in 0.2 M 
Triethanol amine (pH 8.0) for 15min. Crosslinking was stopped by adding 1/10 volume 
of 1M Tris (pH 8.0) and incubating for 2hrs. For each reaction, 1ug of antibody 
crosslinked to dynabeads was added to 1mg of soluble lysate and incubated overnight at 
4°C. Immunoprecipitated proteins were subject to two washes of 15 minutes using lysis 
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buffer and two washes using PBS-T at 4°C. Immunoblots were probed with: purified 
anti-APC-M2 (1:5000), anti-lamin B1 (Oncogene, 1:1000), anti-β-catenin (Sigma, 
1:2000), and anti-α-tubulin (Oncogene, 1:2000).    
Proteomic analysis 
Proteins co-precipitated with purified APC-M2 antibody or preimmunue sera were 
resolved on a 4-12% NUPAGE gel (Invitrogen) and stained using a Colloidal Blue 
Staining Kit (Invitrogen) according to manufacturer’s protocol. The nine gel regions from 
each sample indicated in Figure 4.3 were excised and combined into experimental and 
negative control samples.  These were then equilibrated in 50 mM NH4HCO3, reduced 
with 3 mM DTT in 100 mM NH4HCO3 at 37°C for 15 min, and alkylated with 6 mM 
iodoacetamide in 50 mM NH4HCO3 for 15 min.  The gel pieces were then dehydrated 
with acetonitrile and rehydrated with 15μl of 12.5 mM NH4HCO3 containing 0.01μg/μl 
Modified Trypsin Gold (Promega). Trypsin digestion was carried out for >2 h at 37°C.  
Peptides were extracted with 60% acetonitrile, 0.1% formic acid, dried by vacuum 
centrifugation and reconstituted in 30μl of 0.1% formic acid. 5μl of each peptide 
hydrosylate were analyzed by C18 reverse-phase LC-MS/MS using a Thermo LTQ Ion 
Trap Mass Spectrometer equipped with a Thermo MicroAS Autosampler and Thermo 
Surveyor HPLC Pump, nanospray source, and Xcalibur 1.4 instrument control essentially 
as described (28). Tandem MS data were collected from independent duplicate 
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experiments, and analyzed with the Sequest algorithm to search the UniRef100 database 
(Jan 23 2007, 223514 entries) using Xcorr cutoffs of ≧2 for +2 charged ions and ≧2.5 
for +3 charged ions (29). In addition, the database contained a concatenated decoy 
database with reversed protein sequences to estimate false discovery rates, which were 
5% or below. Proteins identified from negative control were subtracted from 
experimental sample. Only proteins that appeared in both duplicate experiments were 
displayed in Table 1 and Supplemental Table 1.  
Sequential extraction of cytoskeletal elements 
 The protocol for sequential extraction of cells was adapted from protocols previously 
described (30). Briefly, cells were sequentially incubated with cytoskeletal buffer [10mM 
PIPES pH 6.8, 300mM sucrose, 100mM NaCl, 3mM MgCl2, 1mM EGTA and 0.5% 
Triton X-100] and extraction buffer [10 mM PIPES, 250 mM ammonium sulfate, 300 
mM sucrose, 3 mM MgCl2, and 1 mM EGTA] on ice for 5 minutes, digestion buffer [210 
mM PIPES pH 6.8, 300 mM sucrose, 50mM NaCl, 3mM MgCl2, 1mM EGTA, 2 μl /ml 
DNase and 125 μl/ ml RNase I] at 20o C for 20 minutes, and 2M NaCl in PBS on ice for 
5 minutes. Finally, cells were fixed with 4% paraformaldehyde in PBS and subjected to 
immunostaining. 
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DNA constructs, recombinant proteins and fusion protein purification 
To generate recombinant N-terminal His and S dual-tag fused APC fragment M2, the 
corresponding cDNA for APC (amino acid 1000-1326) was amplified using PCR and 
subcloned into a pET-30a(+) vector. The DNA construct encoding GST-fused M2-APC 
(amino acid 959-1338) was a generous gift from Kozo Kaibuchi. Both His-S-M2-APC 
and GST-M2-APC fusion proteins were expressed and purified as described (31, 32).  
Affinity-purification of anti-APC-M2 antibody 
Anti-APC-M2 rabbit serum was generated by injecting purified S-tag fused M2-APC 
as the antigen. Serum was acquired and applied to a column of GST-fused M2-APC 
covalently linked to NHS-Sepharose FastFlow (GE healthcare) according to 
manufacturer’s protocol. After washing with Phosphate Buffered Saline (PBS) plus 0.1% 
Tween-20 (PBS-T) to remove non-specific proteins, bound antibodies were eluted from 
the antigen column with 0.2 M Glycine (pH 2.0). Eluted antibodies were dialyzed with 
PBS containing 10% Glycerol and concentrated by centrifugal concentrator to 1mg/ml. 
Affinity-purified antibody was stored at 4°C with preservatives and is referred to as 
APC-M2 pAb. 
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Results  
Intermediate Filament protein lamin B1 co-precipitates with APC using the new 
APC-M2 pAb 
As a multi-functional tumor suppressor protein, APC has been widely analyzed 
regarding its subcellular localization and its interaction with other proteins. Most 
commercial antibodies, which were raised against either the N- or C-terminus of APC, 
recognize proteins other than APC (22, 33). This cross reactivity makes it difficult to 
obtain reliable data using many molecular and cellular techniques to study APC. Thus, 
we affinity-purified rabbit sera raised against a central domain of APC (amino acid 
959-1338, Figure 4.1), referred to hereafter as APC-M2 pAb. Most of the following 
studies utilized HCT116βw cells that express only the wild-type β-catenin allele (34), 
unlike the parental HCT116 cells that contain one wild-type and one mutant β-catenin 
allele. APC-M2 pAb recognizes full-length APC migrating as a single band of ~310 kDa 
from HCT116βw cells and truncated mutant APC at ~150kDa from SW480 cells (Figure 
4.2A). No band was detected from HCA46 cells which encode a severely truncated APC 
(amino acid 1-213). Both full-length and truncated APC were efficiently precipitated 
using APC-M2 pAb (Figure 4.2B). A Well established binding partner of APC, β-catenin, 
was also co-precipitated with full-length APC from HCT116βw cell lysates (Figure 4.2B)
Figure 4.1 
Generation of recombinant M2-APC immunogen. (A) Schematic diagram of the 
N-terminal His and S dual-tag fused APC fragment (amino acid 1000-1326) which 
contains the three 15 amino acid repeats and one 20 amino acid repeat. (B) Purified 
recombinant M2-APC fragment (~50kDa) used for immunization was resolved by 
SDS-PAGE and detected using colloidal blue. 
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Figure 4.2
Lamin B1 co-precipitates with endogenous APC using APC-M2 pAb. (A) APC-M2 pAb spe-
cifically detects full-length (~310kDa) APC in HCT116bw cell lysates (lane 1) and truncated 
(~150kDa) APC in SW480 cell lysates (lane 2) by immunoblot. APC-M2 pAb does not detect 
the truncated APC (amino acid 1-213) in HCA46 cell lysates (lane 3).  Equivalent total protein 
(30 mg) was resolved in each lane. Blot shows entire spectrum of proteins from > 300 kDa to 
~ 15 kDa. a-tubulin is shown as a loading control. (B) APC-M2 pAb immunoprecipitates APC 
from HCT116bw (left panel) and SW480 (right panel) cell lysates. b-catenin co-precipitates 
with full-length APC (left panel, middle blot). Neither APC nor b-catenin co-precipitated with 
preimmunue sera (Preim). P, precipitated proteins; S, 10% of non-precipitated supernatant 
proteins (27mg). Input, 5% of total input proteins (25mg). (C) Endogenous lamin B1 was co-
precipitated with APC using APC-M2 pAb, but not with preimmune sera. Input, 6% of total 
input proteins (37.5 mg). The lower band in the APC IP lane represents degradation products.
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Thus, we confirmed the reliability of APC-M2 pAb for use in immunoblotting, and 
immunoprecipitation.  
APC is a multi-functional protein involved in several different cellular pathways.  
Many of APC’s functions, such as in cytoskeletal regulation, are only beginning to be 
elucidated. Identifying novel binding partners for APC is a step toward fully 
understanding APC’s involvement in maintenance of cellular integrity. Therefore, 
APC-M2 pAb was used to co-immunoprecipitate APC and its associated proteins from 
HCT116βw cell lysates. Nine protein bands that were unique to the APC co-precipitation 
but not seen using preimmune sera were visualized by colloidal blue staining (Figure 4.3). 
These bands and corresponding regions from the control lane were separately isolated, 
pooled and analyzed by Liquid Chromatography Tandem Mass Spectrometry 
(LC-MS/MS) as described in Methods. Forty-three potential APC binding proteins, 
which have cross-correlation scores (x-corr) of ≧2 for 2+ ion and ≧2.5 for 3+ ion, 
were found following procedures described in Methods (Table 4.1). These 43 proteins 
could be grouped in eight broad categories, the largest two being cytoskeletal regulation 
and RNA processing/translation.  From the most abundant potential APC-binding 
proteins found, we chose to examine the interaction of APC with intermediate filaments  
in more detail. IF proteins identified were lamin B1, lamin B2, keratin 81 and keratin 82 
(Table 4.2). Initially, we focused on lamin B1, the most abundantly APC-associated 
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protein of the four. Interaction of lamin B1 with APC was verified by co-precipitation 
(Figure 4.2C).  
Lamin B1 colocalization with APC in both cultured cells and human colonic tissue 
revealed using APC-M2 pAb 
In order to validate the interaction of lamin B1 with APC using immunofluorescence, 
we first verified the utility of APC-M2 pAb for immunofluorescence microscopy. 
APC-M2 pAb revealed APC at cell-cell junctions, in the nucleus and in the cytoplasm of 
HCT116βw cells (Figure 4.4A). This pattern partially overlapped that of one of the most 
reliable commercially available APC antibodies, ab-7, which was raised against amino 
acid 1-266 (22).  The most intense areas of staining within HCT116βw cells (Figure 
4.4A) resembled localization at the centrosome previously reported by Olmeda and 
Henderson (35, 36). In SW480 cells in particular, APC-M2 pAb revealed more 
immuno-reactivity to APC in the nucleus compared to that of ab-7, the pattern of which 
was described previously (27). Importantly, APC-M2 pAb did not produce any signal in 
HCA46 cells which are predicted to express APC protein lacking the M2 region (Figure 
4.4B). The slight fluorescent signal seen in HCA46 cells stained using APC-M2 pAb was 
similar to that of control cells stained with only secondary antibody (data not shown). 
Using APC-M2 pAb, we found partial overlap in the staining pattern of APC with IF 
proteins lamin B1 and keratin (Figure 4.4C).  
Figure 4.3 
APC-M2 pAb co-precipitates APC binding proteins. Proteins co-precipitated from 
HCT116bw cell lysates using APC-M2 pAb were resolved on a 4-12% NUPAGE gel 
followed by colloidal blue staining. Stars mark the 9 protein bands that were precipitated 
using the APC-M2 pAb and not using preimmune sera. 
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Figure 4.4  
APC colocalizes with IF proteins lamin B1 and keratins in cells. (A) Confocal immuno-
fluorescence microscopy of HCT116bw and SW480 cells double-labeled with APC-M2 
pAb (red) and commercial anti-APC (ab-7) mAb (green). Scale bar, 5mm. (B) Confocal 
immunofluorescence microscopy using APC-M2 pAb to probe HCA46 cells expressing 
N-terminally truncated APC (amino acid 1-213) reveals no signal. Scale bar, 5mm. (C) 
Confocal immunofluorescence microscopy of double-labeled HCT116mw cells reveals that 
a subset of APC (green) protein colocalizes with lamin B1 (red) and keratins (red). Scale 
bar, 5mm.
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Table 4.1 Full list of proteins associated with APC as identified with LC-MS/MS 
 
Peptides 
found Protein 
Accession 
No. 
1st / 2nd run 
Functional category
Adenomatous polyposis coli P25054 89/78 N/A 
Lamin B1 Q6DC98 7/6 
Lamin B2 Q03252 2/3 
Keratin 81 Q14533 5/5 
Keratin 82 Q9NSB4 2/2 
Intermediate filament
α-actinin-4 O43707 4/3 
WD repeat protein 1 O75083 3/3 
Epiplakin P58107 3/2 
Protein phosphatase 1 regulatory 
subunit 12A 
O14974 3/2 
Tubulin α-ubiquitous chain P68363 3/2 
Tubulin β chain P07437 3/2 
Tropomyosin-3  P06753 2/2 
Neurabin-2 Q96SB3 2/2 
α-actinin-1 P12814 2/1 
Cytoskeletal 
regulation 
β-catenin P35222 70/67 
RuvB-like 2 Q9Y230 7/8 
RuvB-like 1 Q9Y265 6/6 
RNA-binding protein 14 Q96PK6 6/7 
Ret finger protein isoform β variant Q59EC6 4/2 
Heterogeneous nuclear 
ribonucleoprotein K 
P61978 3/5 
Pescadillo homolog 1 O00541 2/2 
Transcription 
Protein TFG Q92734 8/6 Chromosome 
rearrangement 
Ladinin 1 O00515 8/8 Extracellular matrix 
40S ribosomal protein S4, Y isoform 1 P22090 8/5 
ATP-dependent RNA helicase DHX15 O43143 7/9 
Splicing factor arginine/serine-rich 1 Q07955 6/4 
Heterogeneous nuclear  
ribonucleoprotein M 
P52272 4/3 
ATP-dependent RNA helicase DDX3X O00571 4/2 
Nucleolar RNA helicase 2 Q9NR30 3/2 
RNA processing & 
translation 
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(Table 4.1 continued)   
Splicing factor 3b, subunit 3 Q6NTI8 2/3 
Heterogeneous nuclear 
ribonucleoprotein Q 
O60506 2/2 
Nuclear fragile X mental 
retardation-interacting protein 2 
Q7Z417 3/3 
Transducin beta-like 3 variant Q59GD6 2/2 
Heat shock 70 kDa protein 2 P54652 7/6 
Heat shock 70kDa protein 5 P11021 4/2 Chaperones 
Liprin-β1 Q86W92 3/5 Tumorigenesis 
LRCH3 precursor Q96II8 5/4 
Transketolase P29401 3/3 Others 
43 proteins; each peptide of which passed Xcorr cutoffs of 2 [+2 ion], 2.5 [+3 ion]; for all 
proteins at least 2 peptides found each duplicate run 
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Table 4.2 Intermediate filament proteins associated with APC as identified with LC-MS/MS  
 
Peptides found 
Protein Accession No 
1st / 2nd run 
Lamin B1 Q6DC98 7/6 
Lamin B2 Q03252 2/3 
Keratin 81 Q14533 5/5 
Keratin 82 Q9NSB4 2/2 
at least 2 peptides found in each duplicate run; all peptides passed 
Xcorr cutoffs of 2 for +2 ion and 2.5 for +3 ion 
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 In normal human colonic tissue, both APC and lamin B1 exhibit increasing 
expression from the bottom of crypts toward the luminal surface (Figure 4.5A-a). A 
higher magnification of the confocal image reveals perinuclear colocalization of APC and 
lamin B1 throughout the crypt (Figure 4.5A-b). Although APC staining in stromal cells 
was faint compared to in the epithelia, there appears to be some colocalization of APC 
with lamin B1 in the stromal cell nuclei located between the crypts. As a positive control, 
we co-stained normal human colonic tissue for β-catenin and APC (Figure 4.5B). 
APC-M2 pAb revealed APC in both nuclei and nucleoli, with a staining pattern partially 
overlapping that of β-catenin as previously described (13, 37).  
APC association with intermediate filament proteins is not dependent on actin or tubulin 
IFs interact with both actin-containing microfilaments and microtubules [see review 
(38)].  Because APC also associates with actin and microtubules, it is possible that the 
co-immunoprecipitation of IF proteins with APC was due to precipitation of a large 
complex of cytoskeletal components.  To determine whether the APC/IF interaction was 
dependent on actin-containing microfilaments and microtubules, we performed a 
traditional solublization and extraction of both tubulin- and actin-containing 
microfilament proteins from cells, leaving behind predominantly insoluble IFs and 
desmosomes (30). After sequential extraction, the cytoskeletal proteins tubulin and actin 
were efficiently removed from cells as determined by immunofluorescence microscopy 
Figure 4.5  
APC colocalizes with lamin B1 in human colonic tissue. Confocal immunofluorescence 
microscopy of cryosections from normal human colon tissue triple-labeled with APC-M2 
pAb (green), DNA dye topro-3 (blue)and lamin B1 (red) (A) or b-catenin mAb (red) (B). 
Scale bars, 20 mm. Tissues are oriented so that luminal surfaces are at the top of the images. 
(b) Enlarged image of the region indicated in (a). (A) APC colocalizes with lamin B1 (red) 
around nuclei.  (B) APC colocalizes with b-catenin in the cytoplasm and cell junctions of 
human colonic crypts. 
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Figure 4.6 
APC remains associated with IF proteins following extraction of actin and tubulin. Left two 
panels, 184A1 epithelial cells analyzed by immunofluorescence microscopy reveals normal 
distribution of APC, lamin B1, keratin, tubulin, actin (detected with phalloidin) and DNA 
(blue in DIC overlay). Right two panels, following sequential extraction, APC remained cell 
associated, along with IF proteins lamin B1 and keratin. Note that actin, tubulin, and DNA 
were successfully extracted from these cells. Nuclei are indicated by DAPI staining. Scale 
bar, 10mm. 
APC
pan-keratin
lamin B1
a&b-tubulin
  F-actin
DIC/DAPI                            DIC/DAPI
Before Extraction                   After Extraction
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(Figure 4.6). APC, however, remained associated with IFs as indicated by lamin B1 and 
pan-keratin staining. Finding APC still associated with cells following this extraction 
procedure suggests a stable interaction between APC and IFs, independent of 
actin-containing microfilaments and microtubules. 
APC-M2 pAb is a versatile antibody, specific for APC 
We have demonstrated that APC-M2 pAb specifically recognizes APC protein in 
cells by immunoblot (Figure 4.2A) and immunoprecipitation (Figure 4.2B-C and Table 
4.1) and in both cells and human tissue by immunofluorescence confocal microscopy 
(Figure 4.4 and 4.5). Many mouse models have been established to analyze APC 
functions in the context of a whole mammalian organism. To validate the use of APC-M2 
pAb in animal studies, frozen sections of mouse intestinal tissue were probed with the 
APC-M2-pAb and then APC was visualized using confocal microscopy. In the small 
intestine, APC appeared at cell-cell junctions and in the cytoplasm (Figure 4.7A and B). 
In enterocytes of the villus, cytoplasmic puncta were also visible, particularly near the 
basal surface (Figures 4.7B).  APC staining was most intense in cells at the top of villi, 
with less APC in cells near the crypt base (Figure 4.7A).  In the colon, APC-M2 pAb 
revealed APC in both nuclei and nucleoli, with a staining pattern partially overlapping 
that of β-catenin as previously described (Figure 4.7C and D) (13, 37). In some cells at 
Figure 4.7 
APC-M2 pAb recognizes endogenous APC protein in mouse intestinal tissue by immunostain-
ing. Confocal immunofluorescence microscopy of cryosections from wild-type mouse ileum (A, 
B) and colon (C, D) tissues triple-labeled with APC-M2 pAb (green), b-catenin mAb (red) and 
DNA dye topro-3 (blue). Scale bars, 20 mm. Tissues are oriented so that luminal surfaces are at 
the top of the images. (A) There is an increasing gradient of APC staining from crypts to villi. 
(B) Enlarged image of a region at the villus tip shown in (A). APC staining is concentrated in 
basolateral regions of villus enterocytes. (D) Enlarged image of a region at the base a colonic 
crypt shown in (C). APC locates to cell junctions, cytoplasm, nucleus, and nucleoli (arrow). Ar-
rowhead indicates spindle-like staining pattern. 
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the base of the crypts, the spindle-like distribution of APC suggested association with 
centrosomes and microtubule organization centers (Figure 4.7D). Of note, APC-M2 pAb 
did not reveal the apical APC distribution in intestinal tissues that has previously been 
attributed to cross reactivity with a non-APC protein (39).  
Discussion 
In the current study, we have generated an APC-M2 pAb that is specific for APC. It is 
versatile and can be used to detect APC in immunostaining, immunoblotting and 
immunoprecipitation. Using this antibody, we identified a novel interaction between APC 
and IFs.  The APC and IF protein interaction was confirmed by co-precipitation and 
colocalization in cultured epithelial cells and human intestinal tissue.  Association of 
APC with IFs is not dependent on actin-containing microfilaments and microtubules.    
APC mutations are found in over 80% of colorectal cancers and have been assessed 
for screening and prognosis purposes in clinical settings. For such research, access to an 
APC antibody that accurately depicts levels and subcellular localizations of APC in cells 
and especially in tissues is extremely important.  According to Wakeman et.al (22), 
many commercially available antibodies also recognize an unidentified protein that 
localizes to the apical region of polarized epithelial cells. Most currently available 
commercial APC antibodies were raised against several hundred amino acids at either the 
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N- or C-terminus of the APC protein. However, most of these antibodies have not been 
proven to be specific for APC (22).  Furthermore, most of these antibodies are only 
useful for a single application.  For example, anti-APC Ab-7 is only effective when used 
for immunostaining.  Therefore, we generated a new antibody against the 15 amino acid 
repeat region in the middle of APC (Figure 4.1). This affinity-purified APC-M2 pAb 
recognizes junctional, cytoplasmic and nuclear APC by immunostaining (Figure 4.4A) 
without producing the non-specific apical staining pattern previously seen (22). 
One of the most clinically relevant applications for APC antibodies is for 
immunohistochemical analysis of tissues. We have validated the use of APC-M2 pAb in 
the immunostaining of sections of frozen human colonic tissue and mouse intestinal 
tissue. Previously, APC has been detected in both the nucleus and cytoplasm of human 
colonic tissue, with more prevalent cytoplasmic staining in colonic tumors compared to 
normal tissue (37). In our study of human colon tissue, APC-M2 pAb revealed APC in 
both nuclei and at cell-cell junctions, partially colocalized with β-catenin, similar to 
previous reports (13, 37) (Figure 4.5A). APC protein also appeared concentrated near the 
basal surface of epithelial cells (Figure 4.5A-a and B-a) as previously reported  (40). In 
the mouse colonic tissue, the spindle-like distribution of APC we observed in some cells 
near the bottom of a crypt (Figure 4.7D) has been previously reported only in cultured 
cancer cell lines (35, 36). APC staining became most intense in cells at the top of villi in 
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the mouse small intestine (Figure 4.7A) and in cells at the luminal surface of the human 
colon (Figure 4.5), consistent with a role for APC in differentiated cells. Most 
importantly, APC-M2 pAb did not recognize any protein at the apical surface of intestinal 
tissues. Thus, APC-M2 pAb does not appear to exhibit the cross reactivity previously 
reported for some commercially available APC antibodies (39). Taken together, the 
APC-M2 pAb is a useful antibody for future examination of APC in mouse and human 
tissue sections. Future analysis of formalin-fixed paraffin-embedded tissues may uncover 
more clinical uses for this antibody. 
Intermediate filaments are essential components of cytoskeletal structure. Recent 
reports have implicated APC in the regulation of cellular structural integrity through 
affects on microtubule growth directionality (41) and polarity (42). APC also associates 
with microtubule-interacting protein EB1 (17), and actin-associated protein ASEF (11). 
Our own previous screen for APC-interacting proteins identified keratin 18 (Stecklein 
and Neufeld, personal communication). Although classified as a hair cuticle-specific 
keratin, keratin 81 is expressed in a wide variety of tissues including mammary gland and 
lung (43-45) and in human embryonic kidney 293T cells (46). Keratin 82 is also thought 
to be expressed predominantly in hair and nail. However, when Flag tag specific 
antibodies were used to immunoprecipitate flag-tagged human homolog 3 of Drosophila 
Disk-large (hDlg) from human embryonic kidney 293 cells, keratin 82 was identified as a 
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protein partner (47).  This observation is significant because it indicates that keratin 82 
has a broader expression pattern than initially suggested and because hDlg protein itself is 
a binding partner of APC (48).  
As a vital part of the cytoskeleton, intermediate filaments are dynamic and can 
stabilize cellular organelles such as the nucleus (49). Mutations in genes encoding IF 
proteins are associated with a number of diseases such as Monilethrix (K81) (50), 
Autosomal dominant leukodystrophy (LMNB1) (51), acquired partial lipodystrophy 
(LMNB2) (52), and various other lipodystrophies and cardiomyopathies (19). APC 
potentially cross-links IFs to improve their stability or binds IFs to other structures such 
as actin filaments or microtubules. Therefore, truncated APC found in the majority of 
colorectal cancers and many other cancers, might have compromised ability to link APC 
binding partners with different IF proteins. Further study of this novel APC/IF interaction 
might illuminate the underlying mechanisms of intermediate filament protein-associated 
diseases. 
Conclusions  
In summary, we identified an interaction between APC and intermediate filament 
proteins lamin B1 and keratin using a new antibody, APC-M2 pAb. The APC-M2 pAb 
antibody is specific for APC, versatile, and reliable, with potential value in the clinical 
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setting and in translational research.  By sequential extraction of cytoskeletal 
components, we have shown that the association of APC with IF proteins is not 
dependent on actin and tubulin.  Finding APC associated with IF proteins confirms and 
expands upon the previous notion that APC is in close association with the cytoskeleton, 
raising the possibility that APC functions in the maintenance of cytoskeletal structure and 
integrity. 
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CHAPTER 5  
DISCUSSION AND FUTURE DIRECTIONS 
As the key regulator to suppress tumorigenesis in colorectal cancers, APC has been 
extensively studied since its discovery in the early 1990s (1, 2). In addition to its 
traditional role as a negative regulator of Wnt signaling, other functions of APC have 
been increasingly emphasized. Despite the large body of work identifying these 
non-traditional roles for APC, most of these functions are only beginning to be 
understood. Therefore, identification of APC binding partners is a powerful approach to 
obtain functional information about APC in multiple pathways. In this work, I identified 
two novel binding partners of APC: topo IIα and lamin B1. Topo IIα mediates APC’s 
function in the regulation of G2-M cell cycle transition; whereas lamin B1 might be 
regulated by APC, thus APC being involved cytoskeletal organization. In chapter 2 & 3, I 
described two regions in APC that specifically bind topo IIα but not topo IIβ. Expression 
of either domain dramatically affects the activity of topo IIα in vitro and in vivo and 
delays cell cycle progression in G2, but only in cells with normal level of topo IIα. For 
the first time, we report a β-catenin independent role for APC in the regulation of G2-M 
transition.  
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I propose that the G2 cell cycle arrest results from inhibition of topo IIα leading to 
mis-regulation of DNA untangling. This inhibition of topo IIα activity seems to occur 
with either M2- of M3-APC, amino acid 959-1338 or 1211-2073, respectively. Most APC 
mutations found associated with colorectal cancers result in truncation of APC protein 
between amino acid 1250 and 1450 (3). Thus, most of M3- and even part of M2-APC are 
lost in colorectal cancers. It will be interesting to determine if truncated APC also inhibits 
topo IIα activity similar to M2- and M3-APC. One approach to analyze this potential is to 
generate a GFP-fused APC1417 (amino acid 1-1417), a region commonly used in 
mammalian systems to mimic truncated APC in human cancers. The topo IIα 
decatenation activity could then be evaluated in nuclear extracts from GFP-APC1417 
expressing cells. Along the same line, it will also be informative to analyze the effect of 
expression of M2- and M3-APC in colonic cancer cell lines with truncated APC, such as 
SW480 and Caco2 cells. Will introduction of M2- or M3-APC also cause G2 cell cycle 
arrest and inhibition of topo IIα activity in nuclear extracts from those cell lines?  
M2- and M3-APC enhanced topo IIα decatenation activity in an in vitro system 
using purified recombinant proteins, but inhibited topo IIα activity in nuclear lysates 
from transfected cells. The different responses potentially stem from lack of 
post-translational modifications in the in vitro system. Phosphorylation of APC has been 
implicated in β-catenin down-regulation, APC nuclear transport and other cellular 
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functions (4-8). Recombinant M2- and M3-APC proteins produced in and purified from 
bacteria are not phosphorylated. This lack of modification might alter the ability of M2- 
and M3-APC to interact with topo IIα and thus their ability to modify topo IIα activity. 
On the other hand, topo IIα has been reported to be phosphorylated, ubiquitinated and 
even SUMOylated in cells (9-12). However, the exact consequence of these 
modifications is not clear. It is possible that APC is involved in some of these topo IIα 
modifications. Therefore, M2- or M3-APC expressed in cells would efficiently mediate 
post-translational modifications of topo IIα, while purified M2- or M3-APC would not. 
In this scenario, regents to identify specifically modified topo IIα or APC will need to be 
developed to facilitate testing of this hypothesis. Alternatively, identifying the effect of 
endogenous full-length APC on topo IIα activity will also be illuminating. Inefficient 
transfection of mammalian cells with expression constructs for full-length APC has been 
an obstacle to exploring this further. Therefore, developing a stable cell line with 
inducible expression of full-length APC will be beneficial as well.  
Inhibiting topo IIα initiates the G2 decatenation checkpoint through ATR kinase and 
cyclin B1 (Figure 1.7) (13). Based on the inhibitory effect of M2- and M3-APC, I 
hypothesize that full-length APC has an inhibitory effect on topo IIα as well (Figure 5.1). 
I predict that full-length APC either directly binds to topo IIα to suppress its activity or 
recruits other factors that restrain its activity. These inhibitory signals could be proteins  
Topo IIa
APC
Figure 5.1
Working model of APC’s role in the regulation of the G2 decatenation checkpoint. If the 
chromosomes are not properly detangled before entering M phase, ATR kinase can be 
activated to initiate the decatenation checkpoint. In this process, APC binds to topo IIα, 
recruits proteins that directly inhibit topo IIα, or brings in molecules that modify topo 
IIα, thus inhibiting topo IIα activity. This inhibition activates the G2 decatenation 
checkpoint, giving the cell time for DNA detangling or further cell fate determination.  
(Modified from Damelin and Bestor, 2007) 
ATR
Plk1
Cyclin B1
WRN BRCA1
G2 M
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that directly suppress topo IIα activity, or intermediate molecules, such as ubiquitin 
ligase, that execute post-translational modifications of topo IIα. Future efforts to 
characterize the components of the APC-topo IIα complex will test this model.  
As the key tumor suppressor in the pathogenesis of colorectal cancer, APC has 
become one of the most intensively studied proteins in both basic and clinical research 
(14-16). Lack of reliable regents to analyze APC expression in both cell and tissue studies 
is a rate limiting step, which holds back translational research. Although progress has 
been made with antibody-based investigations, many commercial available APC 
antibodies non-specifically recognize proteins other than APC (17, 18). This questionable 
antibody specificity adds confusion to the APC research field making interpretation of a 
number of publications regarding APC difficult. Therefore, I generated a specific and 
reliable antiserum, APC-M2 pAb, which will serve as a valuable reagent for future 
immuno-based studies on APC and APC-related colorectal cancers.  
This new APC-M2 pAb is also an efficient tool to identify APC binding proteins. By 
co-immunoprecipitation, I discovered novel interactions between APC and intermediate 
filament proteins. Chapter 4 described characterization of this new APC-M2 pAb 
antibody, as well as identification of the novel APC/intermediate filaments protein 
interaction using APC-M2 pAb for immunoprecipitation. Actin filaments, microtubules 
meshwork and intermediate filaments (IFs) are the three types of cytoskeletal components 
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that collaborate to regulate epithelial integrity, polarity and migration. As a scaffold to 
maintain cell and tissue integrity, defects in IFs impact a number of diseases [see review 
(19)]. Therefore, identification of an interaction between APC with IF proteins might 
help us understand the underlying mechanisms of IF-associated diseases. I speculate that 
APC serves as a bridge to connect actin filaments, microtubules and intermediate 
filaments thus stabilizing epithelial organization. Inactivation of the APC by truncated 
mutation or hypomethylation de-regulates the cytoskeleton by over or under cross-linking 
filaments. Hence, it will be interesting to determine if APC still interacts with IF proteins 
in colonic cancer cells possessing truncated APC. Further functional analysis is required 
to illuminate the exact physiological contribution of APC in cytoskeleton integrity.  
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APPENDIX CHAPTER  
CONDITIONS FOR EXTRACTION AND IMMUNOSTAINING OF  
MOUSE INTESTINAL TISSUES 
Introduction 
In the investigation of colorectal cancers, many mouse models have been established 
and widely studied. Immunohistochemistry (IHC) and immunochemistry (IC) of mouse 
intestinal tissues have been intensively used in pathologic studies. Paraffin embedded 
sections are the best preservation method. However, the antigen retrieval step does not 
always recover the antigen epitopes that are quenched during the complicated embedding 
procedure. Cryo-sections, although better preserving antigen epitopes because of less 
harsh experimental conditions, still have limitations in revealing some antigens. 
Therefore many large antigens that are physiologically unstable, such as APC, can not 
survive the complicated procedures of IHC and IC on paraffin- or cryo-tissues. Further, 
sectioning of tissue, such as colonic tissue, sometimes does not fully retain tissue 
structure, thus cannot give three-dimensional structures. This shortcoming prevents us 
from obtaining structure-related protein distribution in tissue. Thus, we developed an 
immunofluorescence-based method to stain paraformaldehyde (PFA) fixed manually 
micro-dissected intestinal tissues. In the following text, we record the conditions of 
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micro-dissection of mouse intestinal villus and crypts, followed by immunofluorescence 
staining using a few specific commercial antibodies including anti-APC.  
Materials and Methods 
Isolation of mouse intestinal tissues 
 Mice are euthanized by CO2 asphyxiation. Colon and small-intestine tissues removed 
carefully and washed thoroughly with ice-cold PBS. Tissues were fixed with 4% PFA on 
ice for 30min on a piece of Parafilm. Fixed tissue should be stored in PBS at 4°C for 
less than a week to achieve best results.  
 Micro-dissection was performed using a regular dissection microscope. A piece of 
tissue comprised of 10-30 crypts/villi was peeled from the colon/small-intestine tissue 
using the finest micro-dissection quality tweezers. This tiny piece was placed in PBS on a 
glass slide and viewed with the dissection microscope. Single crypt/villus structures were 
isolated carefully using a fine needle made from super fine wires. Isolated crypt/villus 
were then transferred carefully to a 0.5ml eppendorf tube containing 300μl of PBS. 
Tissues were kept on ice during the dissection procedure. Each sample for 
immunofluorescence staining should contain at least 50 crypts/villi. Isolated crypts/villi 
should be kept on ice for 48hrs or less before staining to achieve best results.  
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Immunofluorescence 
Micro-dissected villi or crypts in 300μl of PBS were first permeabilized by 15μl of 
10% Triton X-100/PBS (final concentration of 0.5%) for 1hr at room temperature (RT) 
with gentle agitation. Crypts/villi were collected by spinning at 150Xg for 5min. Then 
crypts/villi were blocked with 200μl MOM Concentrate (VECTOR LABORATORIES) 
overnight at 4°C with gentle agitation, if primary antibodies were made in mouse or rat. 
Otherwise, crypts/villi were blocked in 200 μl of 5% normal goat serum (NGS) (Sigma), 
1% bovine serum albumin (BSA) (Sigma) and 0.1% Triton X-100 in PBS overnight at 4
°C with gentle agitation. Crypts/ villi were then collected by spinning at 150Xg for 
5min. Crypts/villi were then incubated with primary antibodies diluted in 200μl of MOM 
Diluent (VECTOR), if using MOM blocking procedure, or in 200μl of blocking buffer, 
for 24 hrs at 4°C with gentle agitation. Crypts/ villi were then collected by spinning at 
150Xg for 5min. Then, 300-400 μl of TBS-T was added to the tube. All contents in the 
tube were then poured into a 15ml conical tube. Repeat this step until all crypts/villi are 
transferred into the conical tube. The final volume of TBS-T was then added to 10ml. 
This washing step should be carried out at 4°C with gentle agitation for 24 hrs. Crypts/ 
villi were then collected by multiple spinning (3-4) and then transferred to a new 0.5ml 
eppendorf tube. Crypts/villi were incubated with Alexa-fluorophore 
conjugated-secondary antibodies overnight at 4°C with gentle agitation in dark. If using 
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primary antibody made in mouse or rat, the secondary antibodies should be pre-absorbed 
with whole-mount intestinal tissue before applying to samples. The washing step and 
spinning steps are essentially the same as that after primary antibody staining. Topro-3 
(1:500, Invitrogen) is used to co-stain crypts/villi for 5min RT. At last, mount crypt/villus 
with Prolong (Invitrogen) on a waterproof pap-pen- (Invitrogen) marked glass slide. 
Confocal Microscopy should be performed within a week for best signals. 
Antibodies 
The following antibodies are used for immunostaining: anti-APC (ab-1, 1:50, 
Oncogene), anti-APC (ab-7, 1:50, Oncogene), anti-APC (ali12-28, 1:2000, Chemicon), 
anti-APC (F3, Oncogene, 1:200), anti-β-catenin (1:2000, Sigma), anti-Musashi-1 (1:200 
R&D), anti-Ki67 (1:200, DAKO), anti-BrdU (1:50, BD Bioscience), 
Alexa488-conjugated Wheat germ agglutinin (1:2000, Invitrogen), anti-Chromogranin A 
(1:100, Abcam), Alexa568-conjugated Phalloidin (1:500, Invitrogen) and anti-Lysozyme 
(1:100, Sigma). 
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Results and Discussions 
Colocalization of APC with β-catenin in mouse colonic tissues 
 β-catenin is one of the most important and the most extensive studied binding 
partners of APC. We examine the colocalization of APC with β-catenin in the mouse 
colonic crypt isolated by manual micro-dissection. APC specific antibody ab-7 is used, 
because it is considered the most reliable commercial available APC antibody for 
immunostaining (1). APC predominately colocalizes with β-catenin at cell-cell junction 
and cytoplasm (Figure app.1.1).  
Immunofluorescence of micro-dissected intestinal tissues has been one of most 
reliable approach to assess APC protein expression by commercial APC antibodies in our 
experience. PFA requires critical conditions to achieve its optimal effect and can be 
reversed if stored at 4C for a long time. However, this is the best method so far working 
for APC–related immunostaining. Since the procedure lasts less than a week, the antigens 
are usually well preserved thus ensuring the antibody efficiently recognizes the antigen. 
Also, the manual micro-dissection also guarantees the integrity of the full structure of 
intestinal tissues, such as a small intestine villus or a colon crypt. 
 158
Molecular markers for cell proliferation and differentiation in mouse intestine 
Loss of APC has been shown to perturb intestinal enterocytes proliferation and 
differentiation (2). APC has also been implicated in stem cell proliferation and 
differentiation (3). In mouse model studies, using cell type specific markers to evaluate 
cell proliferation and differentiation has been widely accepted. Here I describe molecular 
markers that specifically detect intestinal stem cells (using anti-Musashi-1) (Figure 
app.1.2), proliferative cells (anti-Ki67) (Figure app.1.3), and the three major cell types in 
the intestine: goblet cell (Wheat germ agglutinin-WGA) (Figure app.1.4), paneth cell 
(anti-Lysozyme) (Figure app.1.5) and enteroendocrine cell (anti-Chromogranin A) 
(Figure app.1.6). Although Musashi-1 has been proposed to be one of the intestinal stem 
cell markers (4), its specificity has been controversial and needs further validation.   
APC (ab-7)            b-catenin               Topro-3                 Merge
Figure app.1.1
APC (shown in green) and b-catenin (shown in red) specific antibodies recoganize 
endogenous proteins in a mouse colonic crypt. APC and b-catenin colocalizes predomi-
nantly at cell adhesion junctions. Scale bar, 20mm.
Musashi-1                       Topro-3                           Merge
Figure app.1.2
Mushashi-1 specific antibody (shown in green) indicates colonic stem cell/TA cells 
in a mouse colonic crypt. Mushashi-1 predominantly localizes in the cytoplasm. 
Scale bar, 20mm. 
APC (ab-7)              Ki67                     Topro-3                Merge
Figure app.1.3
Ki67 specific antibody (shown in red) specifically marks colonic cells that are proliferative 
in a mouse colon crypt. Ki67 predominantly localizes in the nucleus. Scale bar, 20mm.
      WGA              Phalloidin               Topro-3                Merge
Colon
Small 
Intestine
Figure app.1.4
WGA (shown in green) specifically marks goblet cells in a mouse colon crypt by staining 
mucin secreated by these goblet cells. Phalloidin outlines F-actin. Scale bar, 20mm.
  Lysozyme                      Topro-3                        Merge
Figure app.1.5
Lysozyme specific antibody (shown in red) marks paneth cells in the crypt region of 
the small intestine. Note that paneth cells do not exist in colon. Scale bar, 20mm. 
     WGA            Chromogranin          Topro-3                Merge
Figure app.1.6
WGA (shown in green) and chromogranin specific antibody (shown in red) mark goblet 
cells and enteroendocrine cells, repectively in a mouse colon crypt. Scale bar, 20mm. 
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